Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
  • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C255/00—Carboxylic acid nitriles
  • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
  • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/02—Antidotes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
  • C07C271/06—Esters of carbamic acids
  • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
  • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
  • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
  • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
  • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
  • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
  • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
  • C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
  • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
  • C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
  • C07C311/10—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/56—Ring systems containing three or more rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/40—Oxygen atoms
  • C07D211/44—Oxygen atoms attached in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
  • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
  • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
  • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
  • C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
  • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
  • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
  • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D307/20—Oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D333/30—Hetero atoms other than halogen
  • C07D333/34—Sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/08—Bridged systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2603/00—Systems containing at least three condensed rings
  • C07C2603/02—Ortho- or ortho- and peri-condensed systems
  • C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings

Definitions

• ANTIOXIDANT INFLAMMATION MODULATORS OLEANOLIC ACID
• the present invention relates generally to the fields of biology and medicine. More particularly, it concerns compounds and methods for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.
• autoimmune diseases such as rheumatoid arthritis, lupus, psoriasis, and multiple sclerosis involve inappropriate and chronic activation of inflammatory processes in affected tissues, arising from dysfunction of self vs. non-self recognition and response mechanisms in the immune system.
• neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, neural damage is correlated with activation of microglia and elevated levels of pro-inflammatory proteins such as inducible nitric oxide synthase (iNOS).
• iNOS inducible nitric oxide synthase
• One aspect of inflammation is the production of inflammatory prostaglandins such as prostaglandin E, whose precursors are produced by the enzyme cyclo-oxygenase (COX-2).
• COX-2 cyclo-oxygenase
• High levels of COX-2 are found in inflamed tissues. Consequently, inhibition of COX-2 is known to reduce many symptoms of inflammation and a number of important antiinflammatory drugs (e.g., ibuprofen and celecoxib) act by inhibiting COX-2 activity.
• a class of cyclopentenone prostaglandins e.g., 15- deoxy prostaglandin J2, a.k.a. PGJ2 plays a role in stimulating the orchestrated resolution of inflammation.
• COX-2 is also associated with the production of cyclopentenone prostaglandins. Consequently, inhibition of COX-2 may interfere with the full resolution of inflammation, potentially promoting the persistence of activated immune cells in tissues and leading to chronic, "smoldering" inflammation. This effect may be responsible for the increased incidence of cardiovascular disease in patients using selective COX-2 inhibitors for long periods of time.
• Corticosteroids another important class of anti-inflammatory drugs, have many undesirable side effects and frequently are not suitable for chronic use.
• Newer protein-based drugs, such as anti-TNF monoclonal antibodies have proven to be effective for the treatment of certain autoimmune diseases such as rheumatoid arthritis. However, these compounds must be administered by injection, are not effective in all patients, and may have severe side effects.
• a series of synthetic triterpenoid analogs of oleanolic acid have been shown to be inhibitors of cellular inflammatory processes, such as the induction by IFN- ⁇ of inducible nitric oxide synthase (iNOS) and of COX-2 in mouse macrophages.
• iNOS inducible nitric oxide synthase
• COX-2 in mouse macrophages.
• iNOS inducible nitric oxide synthase
• iNOS inducible nitric oxide synthase
• the disclosure provides compounds of the formula:
• X 1 and X 2 are independently: hydrogen, OR b , NR b R c , or SR b , wherein R b and R c are each independently: hydrogen or hydroxy; alkyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , acyl (c ⁇ 8) , alkoxy (c ⁇ 8) , aryloxy (c ⁇ 8) , acyloxy (c ⁇ 8) , alkylamino (c ⁇ 8) , arylamino (c ⁇ 8) , amido (c ⁇ 8) , or a substituted version of any of these groups; or a substituent convertible in vivo to hydrogen; provided that Rb is absent when the atom to which it is bound is part of a double bond, further provided that when R b is absent the atom to which it is bound is part of a double bond;
• Y is hydroxy, alkoxy (c ⁇ 8) , aryloxy (c ⁇ 8) , acyloxy (c ⁇ 8) , substituted alkoxy (c ⁇ 8) , substituted alkoxy (c ⁇ 8) , substituted aryloxy (c ⁇ 8) , substituted acyloxy (c ⁇ 8) , or NR 1 R 2 , wherein R 1 and R 2 are independently: hydrogen or hydroxy; or alkyl (c ⁇ 12) , alkenyl (c ⁇ 12) , alkynyl (c ⁇ 12) , aryl (c ⁇ 12) , aralkyl (c ⁇ 12) , heteroaryl (c ⁇ 12) , heteroaralkyl (c ⁇ 12) , acyl (c ⁇ 12) , alkoxy (c ⁇ 12) , alkenyloxy (c ⁇ 12) , alkynyloxy (c ⁇ 12) , aryloxy (c ⁇ 12) , aralkoxy (c ⁇ 12) , heteroaryloxy
• R 1' is: hydrogen, cyano, hydroxy, halo, or amino; or alkyl (c ⁇ 8) , alkenyl (c ⁇ 8) , alkynyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , heteroaryl (c ⁇ 8) , heteroaralkyl (c ⁇ 8) , acyl (c ⁇ 8) , alkoxy (c ⁇ 8) , aryloxy (c ⁇ 8) , acyloxy (c ⁇ 8) , alkylamino (c ⁇ 8) , arylamino (c ⁇ 8) , amido (c ⁇ 8) , or a substituted version of any of these groups;
• R 2' is: cyano, hydroxy, halo or amino; or fluoroalkyl (c ⁇ 8) , alkenyl (c ⁇ 8) , alkynyl (c ⁇ 8) , aryl (c ⁇ 8) , heteroaryl (c ⁇ 8) , acyl (c ⁇ 8) , al
• R5 is hydrogen, hydroxy or oxo
• R 7 is hydrogen or hydroxy
• R ⁇ , R9, Rio and Rn are each independently hydrogen, hydroxy, alkyl (c ⁇ 8) , substituted alkyl (c ⁇ 8) , alkoxy (c ⁇ 8) or substituted alkoxy (c ⁇ 8) ; or pharmaceutically acceptable salts, esters, hydrates, solvates, tautomers, prodrugs, or optical isomers thereof.
• the compound is further defined as:
• X 1 and X 2 are independently: hydrogen, OR b , NR b R c , or SR b , wherein R b and R c are each independently: hydrogen; alkyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , acyl (c ⁇ 8) , or a substituted version of any of these groups; or a substituent convertible in vivo to hydrogen; provided that R b is absent when the atom to which it is bound is part of a double bond, further provided that when R b is absent the atom to which it is bound is part of a double bond; Y is hydroxy or NR 1 R 2 , wherein:
• R 1 and R 2 are independently: hydrogen or hydroxy; or alkyl (c ⁇ 12) , alkenyl (c ⁇ 12) , alkynyl (c ⁇ 12) , aryl (c ⁇ 12) , aralkyl (c ⁇ 12) , heteroaryl (c ⁇ 12) , heteroaralkyl (c ⁇ 12) , acyl (c ⁇ 12) , alkoxy (c ⁇ 12) , alkenyloxy (c ⁇ 12) , alkynyloxy (c ⁇ 12) , aryloxy (c ⁇ 12) , aralkoxy (c ⁇ 12) , heteroaryloxy (c ⁇ 12) , heteroaralkoxy (c ⁇ 12) , thioacyl (c ⁇ 12) , alkylsulfonyl (c ⁇ 12) , alkenylsulfonyl (c ⁇ 12) , alkynylsulfonyl (c ⁇ 12) , arylsulfonyl
• the compound is further defined as:
• Xi is: hydrogen, OR b , NR b R c , or SR b , wherein R b and R c are each independently: hydrogen; alkyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , acyl (c ⁇ 8) , or a substituted version of any of these groups; or a substituent convertible in vivo to hydrogen; provided that R b is absent when the atom to which it is bound is part of a double bond, further provided that when Rb is absent the atom to which it is bound is part of a double bond; Ri and R 2 are independently: hydrogen or hydroxy; or alkyl (c ⁇ 12) , alkenyl (c ⁇ 12) , alkynyl (c ⁇ 12) , aryl (c ⁇ 12) , aralkyl (c ⁇ 12) , heteroaryl (c ⁇ 12) , heteroaralkyl (c ⁇ 12) , acyl (c ⁇ 12) ,
• R 2' is: cyano, hydroxy, halo or amino; or fluoroalkyl (c ⁇ 8) , alkenyl (c ⁇ 8) , alkynyl (c ⁇ 8) , aryl (c ⁇ 8) , heteroaryl (c ⁇ 8) , acyl (c ⁇ 8) , alkoxy (c ⁇ 8) , aryloxy (c ⁇ 8) , acyloxy (c ⁇ 8) , alkylamino (c ⁇ 8) , arylamino (c ⁇ 8) , amido (c ⁇ 8) , or a substituted version of any of these groups;
• R ⁇ is: absent or hydrogen; alkyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , acyl (c ⁇ 8) , or a substituted version of any of these groups; or a substituent convertible in vivo to hydrogen; provided that R 3 is absent when the oxygen atom to which it is bound is part of a double bond, further provided that when R 3 is absent the oxygen atom to which it is bound is part of a double bond; and R 4 and R5 are each independently alkyl (c ⁇ 8) or substituted alkyl (c ⁇ 8) ; or pharmaceutically acceptable salts, esters, hydrates, solvates, tautomers, prodrugs, or optical isomers thereof.
• the compound is further defined as:
• X 1 is: hydrogen, OR b , NR b Rc, or SRb, wherein Rb and R c are each independently: hydrogen; alkyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , acyl (c ⁇ 8) , or a substituted version of any of these groups; or a substituent convertible in vivo to hydrogen; provided that Rb is absent when the atom to which it is bound is part of a double bond, further provided that when Rb is absent the atom to which it is bound is part of a double bond; R 1 and R 2 are independently: hydrogen or hydroxy; or alkyl (c ⁇ 12) , alkenyl (c ⁇ 12) , alkynyl (c ⁇ 12) , aryl (c ⁇ 12) , aralkyl (c ⁇ 12) , heteroaryl (c ⁇ 12) , heteroaralkyl (c ⁇ 12) , acyl (c ⁇ 12) , alkoxy (c
• R 2' is: cyano, hydroxy, halo or amino; or fluoroalkyl (c ⁇ 8) , alkenyl (c ⁇ 8) , alkynyl (c ⁇ 8) , aryl (c ⁇ 8) , heteroaryl (c ⁇ 8) , acyl (c ⁇ 8) , alkoxy (c ⁇ 8) , aryloxy (c ⁇ 8) , acyloxy (c ⁇ 8) , alkylamino (c ⁇ 8) , arylamino (c ⁇ 8) , amido (c ⁇ 8) , or a substituted version of any of these groups;
• R 3 is: absent or hydrogen; alkyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , acyl (c ⁇ 8) , or a substituted version of any of these groups; or a substituent convertible in vivo to hydrogen; provided that R 3 is absent when the oxygen atom to which it is bound is part of a double bond, further provided that when R 3 is absent the oxygen atom to which it is bound is part of a double bond; and R 4 and R5 are each independently alkyl (c ⁇ 8) or substituted alkyl (c ⁇ 8) ; or pharmaceutically acceptable salts, esters, hydrates, solvates, tautomers, prodrugs, or optical isomers thereof.
• the compound is further defined as:
• X 1 and X 2 are independently: hydrogen, OR b , NR b Rc, or SRb, wherein Rb and R c are each independently: hydrogen; alkyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , acyl (c ⁇ 8) , or a substituted version of any of these groups; or a substituent convertible in vivo to hydrogen; provided that Rb is absent when the atom to which it is bound is part of a double bond, further provided that when Rb is absent the atom to which it is bound is part of a double bond; R 1 and R 2 are independently: hydrogen or hydroxy; or alkyl (c ⁇ 12) , alkenyl (c ⁇ 12) , alkynyl (c ⁇ 12) , aryl (c ⁇ 12) , aralkyl (c ⁇ 12) , heteroaryl (c ⁇ 12) , heteroaralkyl (c ⁇ 12) , acyl (c ⁇ 12) ,
• the compound is further defined as:
• X 1 is: hydrogen, OR b , NR b R c , or SR b , wherein R b and R c are each independently: hydrogen; alkyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , acyl (c ⁇ 8) , or a substituted version of any of these groups; or a substituent convertible in vivo to hydrogen; provided that Rb is absent when the atom to which it is bound is part of a double bond, further provided that when R b is absent the atom to which it is bound is part of a double bond; Y is hydroxy or NR 1 R 2 , wherein:
• R 1 and R 2 are independently: hydrogen or hydroxy; or alkyl ( c ⁇ i2), alkenyl (c ⁇ 12) , alkynyl (c ⁇ 12) , aryl (c ⁇ 12) , aralkyl (c ⁇ 12) , heteroaryl (c ⁇ 12) , heteroaralkyl (c ⁇ 12) , acyl (c ⁇ 12) , alkoxy (c ⁇ 12) , alkenyloxy (c ⁇ 12) , alkynyloxy (c ⁇ 12) , aryloxy (c ⁇ 12) , aralkoxy (c ⁇ 12) , heteroaryloxy (c ⁇ 12) , heteroaralkoxy (c ⁇ 12) , thioacyl (c ⁇ 12) , alkyl- sulfonyl (c ⁇ 12) , alkenylsulfonyl (c ⁇ 12) , alkynylsulfonyl (c ⁇ 12) , aryl- sul
• R 2' is: cyano, hydroxy, halo or amino; or fluoroalkyl (c ⁇ 8) , alkoxy (c ⁇ 8) , aryloxy (c ⁇ 8) , acyloxy (c ⁇ 8) , alkylamino (c ⁇ 8) , arylamino (c ⁇ 8) , amido (c ⁇ 8) , or a substituted version of any of these groups; and R 4 and R5 are each independently alkyl (c ⁇ 8) or substituted alkyl (c ⁇ 8) ; or pharmaceutically acceptable salts, esters, hydrates, solvates, tautomers, prodrugs, or optical isomers thereof.
• the compound is further defined as:
• R 2' is: cyano, hydroxy, halo or amino; or fluoroalkyl (c ⁇ 8) , alkoxy (c ⁇ 8) , aryloxy (c ⁇ 8) , acyloxy (c ⁇ 8) , alkylamino (c ⁇ 8) , arylamino (c ⁇ 8) , amido (c ⁇ 8) , or a substituted version of any of these groups;
• R 1 and R 2 are independently: hydrogen; or alkyl (c ⁇ 12) , alkenyl (c ⁇ 12) , alkynyl (c ⁇ 12) , aryl (c ⁇ 12) , aralkyl (c ⁇ 12) , heteroaryl (c ⁇ 12) , heteroaralkyl (c ⁇ 12) , acyl (c ⁇ 12) , alkylsulphonyl, alkenylsulphonyl (c ⁇ 12) , alkynylsulphonyl (c ⁇ 12) , arylsulphonyl (c ⁇ 12) , aralkylsulphonyl (c ⁇ 12) , heteroarylsulphonyl (c ⁇ 12) , heteroaralkylsulphonyl (c ⁇ 12) , or a substituted version of any of these groups; and
• R 8 , R9, R 10 and R 11 are each independently hydrogen, hydroxy, alkyl (c ⁇ 6), substituted alkyl (c ⁇ 6), alkoxy (c ⁇ 6) or substituted alkoxy (c ⁇ 6); or pharmaceutically acceptable salts, esters, hydrates, solvates, tautomers, prodrugs, or optical isomers thereof.
• the compound is further defined as:
• R 2' is: cyano, hydroxy, halo or amino; or fluoroalkyl (c ⁇ 8) , alkoxy (c ⁇ 8) , aryloxy (c ⁇ 8) , acyloxy (c ⁇ 8) , alkylamino (c ⁇ 8) , arylamino (c ⁇ 8) , amido (c ⁇ 8) , or a substituted version of any of these groups; and R 1 and R 2 are independently: hydrogen; or alkyl (c ⁇ 12) , alkenyl (c ⁇ 12) , alkynyl (c ⁇ 12) , aryl (c ⁇ 12) , aralkyl (c ⁇ 12) , heteroaryl (c ⁇ 12) , heteroaralkyl (c ⁇ 12) , acyl (c ⁇ 12) , alkylsulphonyl, alkenylsulphonyl (c ⁇ 12) , alkynylsulphonyl (c ⁇ 12) , arylsulphonyl (
• the compound is further defined as:
• R 1 and R2 are independently: hydrogen; or alkyl ( c ⁇ i2), alkenyl (c ⁇ 12) , alkynyl ( c ⁇ i2), aryl (c ⁇ 12) , aralkyl ( c ⁇ i2), heteroaryl ( c ⁇ i2), heteroaralkyl (c ⁇ 12) , acyl (c ⁇ 12) , alkylsulphonyl, alkenylsulphonyl (c ⁇ 12) , alkynylsulphonyl (c ⁇ 12) , arylsulphonyl (c ⁇ 12) , aralkylsulphonyl (c ⁇ 12) , heteroarylsulphonyl (c ⁇ 12) , heteroaralkylsulphonyl (c ⁇ 12) , or a substituted version of any of these groups; or pharmaceutically acceptable salts, esters, hydrates, solvates, tautomers, prodrugs, or optical isomers thereof.
• the compound is further defined as:
• R 1 and R 2 are independently: hydrogen; or alkyl (c ⁇ 12) , alkenyl (c ⁇ 12) , alkynyl (c ⁇ 12) , aryl (c ⁇ 12) , aralkyl (c ⁇ 12) , heteroaryl (c ⁇ 12) , heteroaralkyl (c ⁇ 12) , acyl (c ⁇ 12) , alkylsulphonyl, alkenylsulphonyl (c ⁇ 12) , alkynylsulphonyl (c ⁇ 12) , arylsulphonyl (c ⁇ 12) , aralkylsulphonyl (c ⁇ 12) , heteroarylsulphonyl (c ⁇ 12) , heteroaralkylsulphonyl (c ⁇ 12) , or a substituted version of any of these groups; or pharmaceutically acceptable salts, esters, hydrates, solvates, tautomers, prodrugs, or optical isomers thereof.
• X 1 or X 2 is OR b , wherein R b is absent. In some variations of one or more of the above embodiments, X 1 is ORb and Rb is absent. In some variations of one or more of the above embodiments, X 2 is hydrogen. In some variations of one or more of the above embodiments, Y is hydroxy. In some variations of one or more of the above embodiments, Y is NR 1 R 2 . In some variations of one or more of the above embodiments, R 1 or R 2 is hydrogen. In some variations of one or more of the above embodiments, R 1 and R 2 are each hydrogen. In some variations of one or more of the above embodiments, R 1 or R 2 comprises a fluoro group.
• R 1 or R 2 comprises a trifluoromethyl group.
• R 1 and R 2 are each independently hydrogen, alkyl (c ⁇ 8) , aryl (C ⁇ 10) , aralkyl (C ⁇ 10) , heteroaryl (C ⁇ 10) , heteroaralkyl (C ⁇ 10) , or a substituted version of any of these groups.
• R 2 is alkyl (c ⁇ 8) , In some variations of one or more of the above embodiments, R 2 is alkyl(C3- 12 ) or substituted alkyl(C3- 12 ).
• R 2 is alkyl (c ⁇ 4) or substituted alkyl (c ⁇ 4). In some variations of one or more of the above embodiments, R 2 is alkylsulphonyl (c ⁇ 8) , arylsulphonyl (c ⁇ 8) , aralkylsulphonyl (c ⁇ 8) , heteroarylsulphonyl (c ⁇ 8) , heteroaralkylsulphonyl (c ⁇ 8) , or a substituted version of any of these groups.
• R 2 is alkylsulphonyl (c ⁇ 8) or substituted alkylsulphonyl (c ⁇ 8) , In some variations of one or more of the above embodiments, R 2 is alkylsulphonyl (c ⁇ 8) , In some variations of one or more of the above embodiments, R 2 is substituted alkylsulphonyl (c ⁇ 8) . In some variations of one or more of the above embodiments, R 2 is arylsulphonyl (c ⁇ 8) . In some variations of one or more of the above embodiments, R 2 is heteroarylsulphonyl (c ⁇ 8) . In some variations of one or more of the above embodiments, R 2 is acyl (c ⁇ 10) .
• R 2 is substituted acyl (c ⁇ 10) .
• R 1' is hydrogen.
• R 2' is cyano.
• R 2' is -CF 3 .
• R 3 is absent.
• R 4 and R5 are the same.
• R 4 and R 5 are each alkyl ( c ⁇ 4) .
• R 4 and R5 are each methyl.
• R 6 and R 7 are each hydrogen.
• the bond joining carbon 1 and carbon 2 is a double bond.
• the bond joining carbon 9 and carbon 11 is a double bond.
• the bond joining carbon 9 and carbon 11 is a single bond.
• the bond joining carbon 12 and carbon 13 is a single bond.
• the bond joining carbon 13 and carbon 18 is a single bond.
• Examples of specific compounds provided by the present disclosure include: (4aR,6aR,6bR,8aS,12aS,12bR,14aR,14bR)-8a-amino-4,4,6a,6b,l 1,11, 14b- heptamethyl-3,13-dioxo-3,4,4a,5,6,6a,6b,7,8,8a,9,10,l l,12,12a,12b,13,14,14a,14b- icosahydropicene-2-carbonitrile;
• X 1 and X 2 are independently: hydrogen, OR b , NR b R c , or SR b , wherein R b and R c are each independently: hydrogen; alkyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , acyl (c ⁇ 8) , or a substituted version of any of these groups; or provided that R b is absent when the atom to which it is bound is part of a double bond, further provided that when R b is absent the atom to which it is bound is part of a double bond; R 1' is: hydrogen, cyano, hydroxy, halo, or amino; or alkyl (c ⁇ 8) , alkenyl (c ⁇ 8) , alkynyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , heteroaryl (c ⁇ 8) , heteroaralkyl (c ⁇ 8) , acyl (c ⁇ 8) , alkoxy
• R 1' is hydrogen.
• R 2' is cyano.
• R 3 is absent.
• X 2 is hydrogen.
• the bond joining carbon 1 and carbon 2 is a double bond.
• the bond joining carbon 9 and carbon 11 is a double bond.
• the compound of formula (XI) is further defined as:
• a further embodiment contemplated by the present disclosure is A compound of the formula:
• X 1 is hydrogen, ORb, NRbR c , or SRb, wherein Rb and R c are each independently: hydrogen; alkyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , acyl (c ⁇ 8) , or a substituted version of any of these groups; or provided that Rb is absent when the atom to which it is bound is part of a double bond, further provided that when R b is absent the atom to which it is bound is part of a double bond; R 1' is: hydrogen, cyano, hydroxy, halo, or amino; or alkyl (c ⁇ 8) , alkenyl (c ⁇ 8) , alkynyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , heteroaryl (c ⁇ 8) , heteroaralkyl (c ⁇ 8) , acyl (c ⁇ 8) , alkoxy (c ⁇ 8) , aryloxy (c ⁇ ⁇
• X 1 is OR b and R b is absent.
• R 4 and R 5 are each independently alkyl ( c ⁇ 4) .
• R 4 and R 5 are each methyl in certain embodiments.
• R 6 and R 7 are each hydrogen.
• compounds comprising a bond between carbons 13 and 18, the bond joining carbon 13 and carbon 18 is a single bond.
• the compound of formula (XII) is further defined as:
• Another general aspect of the present disclosure contemplates a compound of the formula:
• X 1 is -OR b , wherein R b is hydrogen: provided that R b is absent when the oxygen atom to which it is bound is part of a double bond, further provided that when Rb is absent the oxygen atom to which it is bound is part of a double bond;
• Y 1 is hydroxy, -CHO, or -OC(O)H:
• R 2' is hydrogen or -C(H)(OH);
• R 3 is absent or hydrogen; provided that R 3 is absent when the oxygen atom to which it is bound is part of a double bond, further provided that when R 3 is absent the oxygen atom to which it is bound is part of a double bond; or salts, esters, hydrates, solvates, tautomers, or optical isomers thereof.
• the compound of formula (XIII) is further defined as:
• compounds of the present disclosure are in the form of pharmaceutically acceptable salts. In other embodiments, compounds of the present disclosure are not be in the form of a salt. In certain embodiments, a compound of the present disclosure is a hydrate. In other embodiments, a compound of the present disclosure is not a hydrate. In certain embodiments, a compound of the present disclosure is a solvate. In other embodiments, a compound of the present disclosure is not a solvate.
• compounds of the present disclosure can be esters of the above formulas.
• the ester may, for example, result from a condensation reaction between a hydroxy group of the formula and the carboxylic acid group of biotin.
• a compound of the present disclosure is not an ester.
• the compounds of the present disclosure can be present as a mixture of stereoisomers. In certain embodiments, compounds of the present disclosure are present as predominantly one optical isomer. In other embodiments, the compounds of the present disclosure are present as single stereoisomers. In some embodiments, compounds of the present disclosure may be inhibitors of IFN- ⁇ -induced nitrous oxide (NO) production in macrophages, for example, having an IC 5O value of less than 0.2 ⁇ M.
• NO IFN- ⁇ -induced nitrous oxide
• compositions comprising as an active ingredient a compound of the present disclosure and a pharmaceutically acceptable carrier.
• the composition may, for example, be adapted for administration by a route selected from the group consisting of orally, intraadiposally, intraarterially, intraarticularly, intracranially, intradermally, intralesionally, intramuscularly, intranasally, intraocularally, intrapericardially, intraperitoneally, intrapleurally, intraprostaticaly, intrarectally, intrathecally, intratracheally, intratumorally, intraumbilically, intravaginally, intravenously, intravesicularlly, intravitreally, liposomally, locally, mucosally, orally, parenterally, rectally, subconjunctival, subcutaneously, sublingually, topically, transbuccally, transdermally, vaginally, in cremes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via
• the composition may be formulated for oral delivery.
• the composition is formulated as a hard or soft capsule, a tablet, a syrup, a suspension, a wafer, or an elixir.
• the soft capsule is a gelatin capsule.
• Certain compositions may comprise a protective coating, such as those compositions formulated for oral delivery.
• Certain compositions further comprise an agent that delays absorption, such as those compositions formulated for oral delivery.
• Certain compositions may further comprise an agent that enhances solubility or dispersibility, such as those compositions formulated for oral delivery.
• Certain compositions may comprise a compound of the present disclosure, wherein the compound is dispersed in a liposome, an oil and water emulsion or a water and oil emulsion.
• Yet another general aspect of the present disclosure contemplates a therapeutic method comprising administering a pharmaceutically effective amount of a compound of the present disclosure to a subject.
• the subject may, for example, be a human.
• These or any other methods of the present disclosure may further comprise identifying a subject in need of treatment.
• Another method of the present disclosure contemplates a method of treating cancer in a subject, comprising administering to the subject a pharmaceutically effective amount of a compound of the present disclosure.
• the cancer may be any type of cancer, such as a carcinoma, sarcoma, lymphoma, leukemia, melanoma, mesothelioma, multiple myeloma, or seminoma.
• Other types of cancers include cancer of the bladder, blood, bone, brain, breast, central nervous system, colon, endometrium, esophagus, genitourinary tract, head, larynx, liver, lung, neck, ovary, pancreas, prostate, spleen, small intestine, large intestine, stomach, or testicle.
• the subject may be a primate. This or any other method may further comprise identifying a subject in need of treatment.
• the subject may have a family or patient history of cancer.
• the subject has symptoms of cancer.
• the compounds of the invention may be administered via any method described herein, such as locally.
• the compound is administered by direct intratumoral injection or by injection into tumor vasculature.
• the compounds may be administered systemically.
• the compounds may be administered intravenously, intra-arterially, intramuscularly, intraperitoneally, subcutaneously or orally, in certain embodiments.
• the pharmaceutically effective amount is 0.1 - 1000 mg/kg. In certain embodiments, the pharmaceutically effective amount is administered in a single dose per day. In certain embodiments, the pharmaceutically effective amount is administered in two or more doses per day.
• the compound may be administered by contacting a tumor cell during ex vivo purging, for example.
• the method of treatment may comprise any one or more of the following: a) inducing cytotoxicity in a tumor cell; b) killing a tumor cell; c) inducing apoptosis in a tumor cell; d) inducing differentiation in a tumor cell; or e) inhibiting growth in a tumor cell.
• the tumor cell may be any type of tumor cell, such as a leukemia cell.
• ⁇ cancer cells include, for example, a bladder cancer cell, a breast cancer cell, a lung cancer cell, a colon cancer cell, a prostate cancer cell, a liver cancer cell, a pancreatic cancer cell, a stomach cancer cell, a testicular cancer cell, a brain cancer cell, an ovarian cancer cell, a lymphatic cancer cell, a skin cancer cell, a brain cancer cell, a bone cancer cell, or a soft tissue cancer cell.
• Combination treatment therapy is also contemplated by the present disclosure.
• the method may further comprise a treatment selected from the group consisting of administering a pharmaceutically effective amount of a second drug, radiotherapy, gene therapy, and surgery.
• Such methods may further comprise (1) contacting a tumor cell with the compound prior to contacting the tumor cell with the second drug, (2) contacting a tumor cell with the second drug prior to contacting the tumor cell with the compound, or (3) contacting a tumor cell with the compound and the second drug at the same time.
• the second drug may, in certain embodiments, be an antibiotic, anti-inflammatory, anti-neoplastic, anti-proliferative, anti-viral, immunomodulatory, or immunosuppressive.
• the second drug may be an alkylating agent, androgen receptor modulator, cytoskeletal disruptor, estrogen receptor modulator, histone-deacetylase inhibitor, HMG-CoA reductase inhibitor, prenyl-protein transferase inhibitor, retinoid receptor modulator, topoisomerase inhibitor, or tyrosine kinase inhibitor.
• the second drug is 5-azacitidine, 5-fluorouracil, 9-cis- retinoic acid, actinomycin D, alitretinoin, all-trans-retinoic acid, annamycin, axitinib, belinostat, bevacizumab, bexarotene, bosutinib, busulfan, capecitabine, carboplatin, carmustine, CD437, cediranib, cetuximab, chlorambucil, cisplatin, cyclophosphamide, cytarabine, dacarbazine, dasatinib, daunorubicin, decitabine, docetaxel, dolastatin-10, doxifluridine, doxorubicin, doxorubicin, epirubicin, erlotinib, etoposide, etoposide, gef ⁇ tinib, gemcitabine, gemtuzumab
• Methods of treating or preventing a disease with an inflammatory component in a subject comprising administering to the subject a pharmaceutically effective amount of a compound of the present disclosure are also contemplated.
• the disease may be, for example, lupus or rheumatoid arthritis.
• the disease may be an inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
• the disease with an inflammatory component may be a cardiovascular disease.
• the disease with an inflammatory component may be diabetes, such as type 1 or type 2 diabetes.
• Compounds of the present disclosure may also be used to treat complications associated with diabetes.
• Such complications include, for example, obesity, hypertension, atherosclerosis, coronary heart disease, stroke, peripheral vascular disease, hypertension, nephropathy, neuropathy, myonecrosis, retinopathy and metabolic syndrome (syndrome X).
• the disease with an inflammatory component may be a skin disease, such as psoriasis, acne, or atopic dermatitis.
• Administration of a compound of the present disclosure in treatment methods of such skin diseases may be, for example, topical or oral.
• the disease with an inflammatory component may be metabolic syndrome (syndrome X).
• a patient having this syndrome is characterized as having three or more symptoms selected from the following group of five symptoms: (1) abdominal obesity; (2) hypertriglyceridemia; (3) low high-density lipoprotein cholesterol (HDL); (4) high blood pressure; and (5) elevated fasting glucose, which may be in the range characteristic of Type 2 diabetes if the patient is also diabetic.
• Each of these symptoms is defined in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III), National Institutes of Health, 2001, N1H Publication No. 01-3670, incorporated herein by reference.
• Another general method of the present disclosure entails a method of treating or preventing a cardiovascular disease in a subject, comprising administering to the subject a pharmaceutically effective amount of a compound of the present disclosure.
• the cardiovascular disease may be, for example, atherosclerosis, cardiomyopathy, congenital heart disease, congestive heart failure, myocarditis, rheumatic heart disease, valve disease, coronary artery disease, endocarditis, or myocardial infarction. Combination therapy is also contemplated for such methods.
• such methods may further comprise administering a pharmaceutically effective amount of a second drug.
• the second drug may be, for example, a cholesterol lowering drug, an anti-hyperlipidemic, a calcium channel blocker, an anti-hypertensive, or an HMG-CoA reductase inhibitor.
• second drugs include amlodipine, aspirin, ezetimibe, felodipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine, nisoldipine or nitrendipine.
• second drugs include atenolol, bucindolol, carvedilol, clonidine, doxazosin, indoramin, labetalol, methyldopa, metoprolol, nadolol, oxprenolol, phenoxybenzamine, phentolamine, pindolol, prazosin, propranolol, terazosin, timolol or tolazoline.
• the second drug may be, for example, a statin, such as atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin or simvastatin.
• a statin such as atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin or simvastatin.
• the neurodegenerative disease may, for example, be selected from the group consisting of Parkinson's disease, Alzheimer's disease, multiple sclerosis (MS), Huntington's disease and amyotrophic lateral sclerosis.
• the neurodegenerative disease is Alzheimer's disease.
• the neurodegenerative disease is MS, such as primary progressive, relapsing- remitting secondary progressive or progressive relapsing MS.
• the subject may be, for example, a primate.
• the subject may be a human.
• the treatment suppresses the demyelination of neurons in the subject's brain or spinal cord.
• the treatment suppresses inflammatory demyelination.
• the treatment suppresses the transection of neuron axons in the subject's brain or spinal cord.
• the treatment suppresses the transection of neurites in the subject's brain or spinal cord.
• the treatment suppresses neuronal apoptosis in the subject's brain or spinal cord.
• the treatment stimulates the remyelination of neuron axons in the subject's brain or spinal cord. In certain embodiments, the treatment restores lost function after an MS attack. In certain embodiments, the treatment prevents a new MS attack. In certain embodiments, the treatment prevents a disability resulting from an MS attack.
• One general aspect of the present disclosure contemplates a method of treating or preventing a disorder characterized by overexpression of iNOS genes in a subject, comprising administering to the subject a pharmaceutically effective amount of a compound of the present disclosure. Another general aspect of the present disclosure contemplates a method of inhibiting
• IFN- ⁇ -induced nitric oxide production in cells of a subject comprising administering to said subject a pharmaceutically effective amount of a compound of the present disclosure.
• Yet another general method of the present disclosure contemplates a method of treating or preventing a disorder characterized by overexpression of COX-2 genes in a subject, comprising administering to the subject a pharmaceutically effective amount of compound of the present disclosure.
• RKD renal/kidney disease
• the RKD may result from, for example, a toxic insult.
• the toxic insult may result from, for example, an imaging agent or a drug.
• the drug may be a chemotherapeutic, for example.
• the RKD may result from ischemia/reperfusion injury, in certain embodiments.
• the RKD results from diabetes or hypertension.
• the RKD may result from an autoimmune disease.
• the RKD may be further defined as chronic RKD, or acute RKD.
• the subject has undergone or is undergoing dialysis.
• the subject has undergone or is a candidate to undergo kidney transplant.
• the subject may be a primate.
• the primate may be a human.
• the subject in this or any other method may be, for example, a cow, horse, dog, cat, pig, mouse, rat or guinea pig.
• Also contemplated by the present disclosure is a method for improving glomerular filtration rate or creatinine clearance in a subject, comprising administering to the subject a pharmaceutically effective amount of a compound of the present disclosure.
• Methods of synthesizing compounds of the present disclosure are also contemplated.
• such methods comprise a method of making a first compound defined as: wherein: X 1 and X 2 are independently: hydrogen, OR b , NR b R c , or SR b , wherein R b and R c are each independently: hydrogen; alkyl (c ⁇ 8) , aryl (c ⁇ 8) , aralkyl (c ⁇ 8) , acyl (c ⁇ 8) , or a substituted version of any of these groups; or a substituent convertible in vivo to hydrogen; provided that R b is absent when the atom to which it is bound is part of a double bond, further provided that when R b is absent the atom to which it is bound is part of a double bond; Y is NR 1 R 2 , wherein: R 1 and R 2 are independently: hydrogen or hydroxy; or alkyl (c ⁇ 12) , alkenyl (c ⁇ 12) , alkynyl (c ⁇ 12) , aryl (c ⁇ 12) , a
• Kits are also contemplated by the present disclosure, such as a kit comprising: a compound of the present disclosure; and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the compound is to be administered, storage information for the compound, dosing information and instructions regarding how to administer the compound.
• the kit may comprise a compound of the present disclosure in a multiple dose form.
• an article of manufacture may comprise a compound of the present disclosure; and packaging materials.
• the packaging materials may comprise a container for housing the compound, in certain embodiments.
• the container may comprise, for example, a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered, storage information, dosing information and/or instructions regarding how to administer the compound.
• the article of manufacture comprises the compound in a multiple dose form.
• the invention provides compounds that may prevent and/or treat diseases or disorders whose pathology involves oxidative stress, inflammation, and/or dysregulation of inflammatory signaling pathways.
• the diseases or disorders can be characterized by overexpression of inducible nitric oxide synthase (iNOS) and/or inducible cyclooxygenase (COX-2) in affected tissues.
• the diseases or disorders can be characterized by overproduction of reactive oxygen species (ROS) or reactive nitrogen species (RNS) such as superoxide, hydrogen peroxide, nitric oxide or peroxynitrite in affected tissues.
• ROS reactive oxygen species
• RNS reactive nitrogen species
• the disease or disorder is characterized by excessive production of inflammatory cytokines or other inflammation- related proteins such as TNF ⁇ , IL-6, IL-I, IL-8, ICAM-I, VCAM-I, and VEGF.
• diseases or disorders may, in some embodiments, involve undesirable proliferation of certain cells, as in the case of cancer (e.g., solid tumors, leukemias, myelomas, lymphomas, and other cancers), fibrosis associated with organ failure, or excessive scarring.
• cancer e.g., solid tumors, leukemias, myelomas, lymphomas, and other cancers
• fibrosis associated with organ failure fibrosis associated with organ failure
• Non limiting examples of the disease or disorder include: lupus, rheumatoid arthritis, juvenile-onset diabetes, multiple sclerosis, psoriasis, and Crohn's disease.
• cardiovascular diseases such as atherosclerosis, heart failure, myocardial infarction, acute coronary syndrome, restenosis following vascular surgery, hypertension, and vasculitis
• neurodegenerative or neuromuscular diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS, and muscular dystrophy
• neurological disorders such as epilepsy and dystonia
• neuropsychiatric conditions such as major depression, bipolar disorder, post-traumatic stress disorder, schizophrenia, anorexia nervosa, ADHD, and autism-spectrum disorders
• retinal diseases such as macular degeneration, diabetic retinopathy, glaucoma, and retinitis
• chronic and acute pain syndromes including inflammatory and neuropathic pain
• hearing loss and tinnitus diabetes and complications of diabetes, including metabolic syndrome, diabetic nephropathy, diabetic neuropathy, and diabetic ulcers
• respiratory diseases such as asthma, chronic obstructive pulmonary disease, acute respiratory distress syndrome, and cystic fibrosis
• Non-limiting examples of compounds disclosed herein include:
• FIGS. 1-34 and 49-52 Inhibition of NO Production.
• RAW264.7 macrophages were pre -treated with DMSO or drugs at various concentrations (nM) for 2 hours, then treated with 20 ng/ml IFN ⁇ for 24 hours. NO concentration in media was determined using the Griess reagent system; cell viability was determined using WST-I reagent.
• FIG. 35 Suppression of iNOS niRNA induction.
• RAW264.7 mouse macrophages were pre-treated for 2 hours with compounds at the indicated concentrations and subsequently stimulated with 10 ng/ml IFN ⁇ for an additional 2 hours.
• mRNA levels of iNOS were quantified by qPCR and are shown relative to the vehicle-treated IFN ⁇ -stimulated sample which was normalized to a value of 1. Values are averages of duplicate PCR reactions, each with triplicate wells.
• FIG. 36 Suppression of iNOS mRNA induction.
• RAW264.7 mouse macrophages were pre-treated for 2 hours with compounds at the indicated concentrations and subsequently stimulated with 10 ng/ml IFN ⁇ for an additional 2 hours.
• mRNA levels of iNOS were quantified by qPCR and are shown relative to the vehicle-treated IFN ⁇ -stimulated sample which was normalized to a value of 1. Values are averages of duplicate PCR reactions, each with triplicate wells.
• FIG. 37 Suppression of iNOS mRNA induction.
• RAW264.7 mouse macrophages were pre-treated for 2 hours with compounds at the indicated concentrations and subsequently stimulated with 10 ng/ml IFN ⁇ for an additional 2 hours.
• mRNA levels of iNOS were quantified by qPCR and are shown relative to the vehicle-treated IFN ⁇ -stimulated sample which was normalized to a value of 1. Values are averages of duplicate PCR reactions, each with triplicate wells.
• FIGS. 38-40 iNOS Western Blot in RAW264.7 mouse macrophages. Cells were pretreated by compounds at 300 nM for 2 hours, followed by 24 hour induction by IFN ⁇ (20 ng/ml).
• FIGS. 41-42 Suppression of IL-6 Induced STAT3 Phosphorylation.
• HeLa cells were treated with DMSO or the indicated compounds at 2 ⁇ M for 6 hours and subsequently stimulated with 20 ng/ml IL-6 for 15 minutes.
• Phosphorylated STAT3 and total STAT3 levels were assayed by immunob lotting.
• FIG. 43 Induction of HO-1.
• FIGS. 43 A and 43B MDA-MB-435 human melanoma cells were treated with vehicle (DMSO) or the indicated compounds and concentrations for 16 hours. HO-I mRNA levels were quantified using qPCR and were normalized relative to a DMSO-treated sample run in parallel. Values are averages of duplicate wells.
• FIG. 43C MDA-MB-435 cells were treated with vehicle (DMSO) or the indicated compounds at 400 nM for 16 hours. HO-I, TrxRl and actin protein levels were assayed by immunoblotting. Actin served as a loading control.
• FIGS. 44A-C, 45A- C, 46A-C, 47A-C: MDA-MB-435 human melanoma cells were treated with vehicle (DMSO) or the indicated compounds (400 nM) for 16 hours.
• HO-I, thioredoxin reductase- 1 (TrxRl), and ⁇ -glutamylcysteine synthetase ( ⁇ -GCS) mRNA levels were quantified using qPCR and were normalized relative to a DMSO-treated sample run in parallel. Values are averages of duplicate wells.
• FIGS. 44D, 46D, 47D: MDA-MB-435 cells were treated with vehicle (DMSO) or the indicated compounds at 400 nM for 16 hours.
• HO-I, TrxRl and actin protein levels were assayed by immunoblotting.
• FIG. 45 Induction of HO-I, TrxRl and ⁇ -GCS.
• FIGS. 45 A-C MDA-MB-435 cells were treated with vehicle (DMSO) or the indicated compounds at 160 nM for 16 hours.
• HO-I, TrxRl, and ⁇ -GCS mRNA levels were quantified by qPCR and were normalized relative to a DMSO-treated sample run in parallel. Values are averages of duplicate wells.
• FIGS. 44D, 46D, 47D MDA-MB-435 cells were treated with vehicle (DMSO) or the indicated compounds at 160 nM for 16 hours.
• HO-I, TrxRl and actin protein levels were assayed by immunoblotting.
• CDDO-TFEA (TP-500) Is Detected at Higher Levels in Mouse Brain than CDDO-EA (TP-319).
• CD-I mice were fed either 200 or 400 mg/kg diet of either TP-319 or TP-500 for 3.5 days, and TP levels in the brains of the mice were analyzed by LC/MS. The structures of TP-319 and TP-500 are shown herein. DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
• Disclosed herein are, for example, new compounds with antioxidant and antiinflammatory properties, methods for their manufacture, and methods for their use, including for the treatment and/or prevention of disease.
• halo means independently -F, -Cl, -Br or -I;
• amino means -NH 2 (see below for definitions of groups containing the term amino, e.g., alkylamino);
• hydroxyamino means -NHOH;
• nitro means -NO 2 ;
• imino means NH (see below for definitions of groups containing the term imino, e.g., alkylamino);
• cyano means -CN;
• azido means -N 3 ;
• mercapto means -SH;
• sulfonamido means -NHS(O) 2 - (see below for definitions of groups containing the term sulfonamido, e.g., alkylsulfonamido);
• sulfonyl means -S(O) 2 - (see below for definitions of groups containing the term sulfony
• (Cn) defines the exact number (n) of carbon atoms in the group.
• (C ⁇ n) defines the maximum number (n) of carbon atoms that can be in the group, with the minimum number of carbon atoms in such at least one, but otherwise as small as possible for the group in question.
• alkenyl (c ⁇ 8) is 2.
• alkoxy (c ⁇ 10) designates those alkoxy groups having from 1 to 10 carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or any range derivable therein (e.g., 3- 10 carbon atoms)).
• Cn-n' defines both the minimum (n) and maximum number (n') of carbon atoms in the group.
• alkyl(c 2 -io) designates those alkyl groups having from 2 to 10 carbon atoms (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10, or any range derivable therein (e.g., 3- 10 carbon atoms)).
• alkyl when used without the "substituted” modifier refers to a non- aromatic monovalent group with a saturated carbon atom as the point of attachment, a linear or branched, cyclo, cyclic or acyclic structure, no carbon-carbon double or triple bonds, and no atoms other than carbon and hydrogen.
• the groups, -CH 3 (Me), -CH 2 CH 3 (Et), -CH 2 CH 2 CH 3 (/i-Pr), -CH(CH 3 ) 2 (iso-P ⁇ ), -CH(CH 2 ) 2 (cyclopropyl), -CH 2 CH 2 CH 2 CH 3 (n- Bu), -CH(CH 3 )CH 2 CH 3 (sec-butyl), -CH 2 CH(CH 3 ) 2 (wo-butyl), -C(CH 3 ) 3 (tert-butyl), -CH 2 C(CH 3 ) 3 (neo-penty ⁇ ), cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexylmethyl are non-limiting examples of alkyl groups.
• substituted alkyl refers to a non-aromatic monovalent group with a saturated carbon atom as the point of attachment, a linear or branched, cyclo, cyclic or acyclic structure, no carbon-carbon double or triple bonds, and at least one atom independently selected from the group consisting of N, O, F, Cl, Br, I, Si, P, and S.
• the following groups are non- limiting examples of substituted alkyl groups: -CH 2 OH, -CH 2 Cl, -CH 2 Br, -CH 2 SH, -CF 3 , -CH 2 CN, -CH 2 C(O)H, -CH 2 C(O)OH, -CH 2 C(O)OCH 3 , -CH 2 C(O)NH 2 , -CH 2 C(O)NHCH 3 , -CH 2 C(O)CH 3 , -CH 2 OCH 3 , -CH 2 OCH 2 CF 3 , -CH 2 OC(O)CH 3 , -CH 2 NH 2 , -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 , -CH 2 CH 2 Cl, -CH 2 CH 2 OH, -CH 2 CF 3 , -CH 2 CH 2 OC(O)CH 3 , -CH 2 CH 2 NHCO 2 C(CH 3 ) 3 , and -
• alkanediyl when used without the "substituted” modifier refers to a non- aromatic divalent group, wherein the alkanediyl group is attached with two ⁇ -bonds, with one or two saturated carbon atom(s) as the point(s) of attachment, a linear or branched, cyclo, cyclic or acyclic structure, no carbon-carbon double or triple bonds, and no atoms other than carbon and hydrogen.
• the groups -CH 2 - (methylene), -CH 2 CH 2 -, -CH 2 C(CH 3 ) 2 CH 2 -,
• substituted alkanediyl refers to a non-aromatic monovalent group, wherein the alkynediyl group is attached with two ⁇ -bonds, with one or two saturated carbon atom(s) as the point(s) of attachment, a linear or branched, cyclo, cyclic or acyclic structure, no carbon- carbon double or triple bonds, and at least one atom independently selected from the group consisting of N, O, F, Cl, Br, I, Si, P, and S.
• the following groups are non- limiting examples of substituted alkanediyl groups: -CH(F)-, -CF 2 -, -CH(Cl)-, -CH(OH)-, -CH(OCH 3 )-, and -CH 2 CH(Cl)-.
• alkenyl when used without the "substituted” modifier refers to a monovalent group with a nonaromatic carbon atom as the point of attachment, a linear or branched, cyclo, cyclic or acyclic structure, at least one nonaromatic carbon-carbon double bond, no carbon-carbon triple bonds, and no atoms other than carbon and hydrogen.
• substituted alkenyl refers to a monovalent group with a nonaromatic carbon atom as the point of attachment, at least one nonaromatic carbon-carbon double bond, no carbon-carbon triple bonds, a linear or branched, cyclo, cyclic or acyclic structure, and at least one atom independently selected from the group consisting of N, O, F, Cl, Br, I, Si, P, and S.
• alkenediyl when used without the "substituted” modifier refers to a nonaromatic divalent group, wherein the alkenediyl group is attached with two ⁇ -bonds, with two carbon atoms as points of attachment, a linear or branched, cyclo, cyclic or acyclic structure, at least one nonaromatic carbon-carbon double bond, no carbon-carbon triple bonds, and no atoms other than carbon and hydrogen.
• alkenediyl groups are non-limiting examples of alkenediyl groups.
• substituted alkenediyl refers to a non-aromatic divalent group, wherein the alkenediyl group is attached with two ⁇ -bonds, with two carbon atoms as points of attachment, a linear or branched, cyclo, cyclic or acyclic structure, at least one nonaromatic carbon-carbon double bond, no carbon-carbon triple bonds, and at least one atom independently selected from the group consisting of N, O, F, Cl, Br, I, Si, P, and S.
• alkynyl when used without the "substituted” modifier refers to a monovalent group with a nonaromatic carbon atom as the point of attachment, a linear or branched, cyclo, cyclic or acyclic structure, at least one carbon-carbon triple bond, and no atoms other than carbon and hydrogen.
• substituted alkynyl refers to a monovalent group with a nonaromatic carbon atom as the point of attachment and at least one carbon-carbon triple bond, a linear or branched, cyclo, cyclic or acyclic structure, and at least one atom independently selected from the group consisting of N, O, F, Cl, Br, I, Si, P, and S.
• the group, -C ⁇ CSi(CH 3 ) 3 is a non-limiting example of a substituted alkynyl group.
• alkynediyl when used without the "substituted” modifier refers to a nonaromatic divalent group, wherein the alkynediyl group is attached with two ⁇ -bonds, with two carbon atoms as points of attachment, a linear or branched, cyclo, cyclic or acyclic structure, at least one carbon-carbon triple bond, and no atoms other than carbon and hydrogen.
• substituted alkynediyl refers to a non-aromatic divalent group, wherein the alkynediyl group is attached with two ⁇ -bonds, with two carbon atoms as points of attachment, a linear or branched, cyclo, cyclic or acyclic structure, at least one carbon-carbon triple bond, and at least one atom independently selected from the group consisting of N, O, F, Cl, Br, I, Si, P, and S.
• the groups -C ⁇ CCFH- and -C ⁇ CHCH(Cl)- are non-limiting examples of substituted alkynediyl groups.
• aryl when used without the "substituted” modifier refers to a monovalent group with an aromatic carbon atom as the point of attachment, said carbon atom forming part of a six-membered aromatic ring structure wherein the ring atoms are all carbon, and wherein the monovalent group consists of no atoms other than carbon and hydrogen.
• substituted aryl refers to a monovalent group with an aromatic carbon atom as the point of attachment, said carbon atom forming part of a six- membered aromatic ring structure wherein the ring atoms are all carbon, and wherein the monovalent group further has at least one atom independently selected from the group consisting of N, O, F, Cl, Br, I, Si, P, and S.
• Non- limiting examples of substituted aryl groups include the groups: -C 6 H 4 F, -C 6 H 4 Cl, -C 6 H 4 Br, -C 6 H 4 I, -C 6 H 4 OH, -C 6 H 4 OCH 3 , -C 6 H 4 OCH 2 CH 3 , -C 6 H 4 OC(O)CH 3 , -C 6 H 4 NH 2 , -C 6 H 4 NHCH 3 , -C 6 H 4 N(CH 3 ) 2 , -C 6 H 4 CH 2 OH, -C 6 H 4 CH 2 OC(O)CH 3 , -C 6 H 4 CH 2 NH 2 , -C 6 H 4 CF 3 , -C 6 H 4 CN, -C 6 H 4 CHO, -C 6 H 4 CHO, -C 6 H 4 C(O)CH 3 , -C 6 H 4 C(O)C 6 H 5 , -C 6 H 4 CO 2 H,
• arenediyl when used without the "substituted” modifier refers to a divalent group, wherein the arenediyl group is attached with two ⁇ -bonds, with two aromatic carbon atoms as points of attachment, said carbon atoms forming part of one or more six-membered aromatic ring structure(s) wherein the ring atoms are all carbon, and wherein the monovalent group consists of no atoms other than carbon and hydrogen.
• arenediyl groups include:
• substituted arenediyl refers to a divalent group, wherein the arenediyl group is attached with two ⁇ -bonds, with two aromatic carbon atoms as points of attachment, said carbon atoms forming part of one or more six-membered aromatic rings structure(s), wherein the ring atoms are all carbon, and wherein the divalent group further has at least one atom independently selected from the group consisting of N, O, F, Cl, Br, I, Si, P, and S.
• aralkyl when used without the "substituted” modifier refers to the monovalent group -alkanediyl-aryl, in which the terms alkanediyl and aryl are each used in a manner consistent with the definitions provided above.
• Non- limiting examples of aralkyls are: phenylmethyl (benzyl, Bn), 1-phenyl-ethyl, 2-phenyl-ethyl, indenyl and 2,3-dihydro- indenyl, provided that indenyl and 2,3-dihydro-indenyl are only examples of aralkyl in so far as the point of attachment in each case is one of the saturated carbon atoms.
• aralkyl When the term “aralkyl” is used with the “substituted” modifier, either one or both the alkanediyl and the aryl is substituted.
• substituted aralkyls are: (3-chlorophenyl)- methyl, 2-oxo-2-phenyl-ethyl (phenylcarbonylmethyl), 2-chloro-2-phenyl-ethyl, chromanyl where the point of attachment is one of the saturated carbon atoms, and tetrahydroquinolinyl where the point of attachment is one of the saturated atoms.
• heteroaryl when used without the “substituted” modifier refers to a monovalent group with an aromatic carbon atom or nitrogen atom as the point of attachment, said carbon atom or nitrogen atom forming part of an aromatic ring structure wherein at least one of the ring atoms is nitrogen, oxygen or sulfur, and wherein the monovalent group consists of no atoms other than carbon, hydrogen, aromatic nitrogen, aromatic oxygen and aromatic sulfur.
• Non-limiting examples of aryl groups include acridinyl, furanyl, imidazoimidazolyl, imidazopyrazolyl, imidazopyridinyl, imidazopyrimidinyl, indolyl, indazolinyl, methylpyridyl, oxazolyl, phenylimidazolyl, pyridyl, pyrrolyl, pyrimidyl, pyrazinyl, quinolyl, quinazolyl, quinoxalinyl, tetrahydroquinolinyl, thienyl, triazinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrrolopyrazinyl, pyrrolotriazinyl, pyrroloimidazolyl, chromenyl (where the point of attachment is one of the aromatic atoms), and chromanyl (where the point of attachment is one of the aromatic atoms).
• substituted heteroaryl refers to a monovalent group with an aromatic carbon atom or nitrogen atom as the point of attachment, said carbon atom or nitrogen atom forming part of an aromatic ring structure wherein at least one of the ring atoms is nitrogen, oxygen or sulfur, and wherein the monovalent group further has at least one atom independently selected from the group consisting of non-aromatic nitrogen, non-aromatic oxygen, non aromatic sulfur F, Cl, Br, I, Si, and P.
• heteroarenediyl when used without the “substituted” modifier refers to a divalent group, wherein the heteroarenediyl group is attached with two ⁇ -bonds, with an aromatic carbon atom or nitrogen atom as the point of attachment, said carbon atom or nitrogen atom two aromatic atoms as points of attachment, said carbon atoms forming part of one or more six-membered aromatic ring structure(s) wherein the ring atoms are all carbon, and wherein the monovalent group consists of no atoms other than carbon and hydrogen.
• heteroarenediyl groups include:
• substituted heteroarenediyl refers to a divalent group, wherein the heteroarenediyl group is attached with two ⁇ -bonds, with two aromatic carbon atoms as points of attachment, said carbon atoms forming part of one or more six-membered aromatic rings structure(s), wherein the ring atoms are all carbon, and wherein the divalent group further has at least one atom independently selected from the group consisting of N, O, F, Cl, Br, I, Si, P, and S.
• heteroarylkyl when used without the “substituted” modifier refers to the monovalent group -alkanediyl-heteroaryl, in which the terms alkanediyl and heteroaryl are each used in a manner consistent with the definitions provided above.
• Non-limiting examples of aralkyls are: pyridylmethyl, and thienylmethyl.
• acyl when used without the "substituted” modifier refers to a monovalent group with a carbon atom of a carbonyl group as the point of attachment, further having a linear or branched, cyclo, cyclic or acyclic structure, further having no additional atoms that are not carbon or hydrogen, beyond the oxygen atom of the carbonyl group.
• the groups, -CHO, -C(O)CH 3 (acetyl, Ac), -C(O)CH 2 CH 3 , -C(O)CH 2 CH 2 CH 3 , -C(O)CH(CH 3 ) 2 , -C(O)CH(CH 2 ) 2 , -C(O)C 6 H 5 , -C(O)C 6 H 4 CH 3 , -C(O)C 6 H 4 CH 2 CH 3 , -COC 6 H 3 (CH 3 ) 2 , and -C(O)CH 2 C 6 Hs, are non-limiting examples of acyl groups.
• acyl therefore encompasses, but is not limited to groups sometimes referred to as “alkyl carbonyl” and “aryl carbonyl” groups.
• substituted acyl refers to a monovalent group with a carbon atom of a carbonyl group as the point of attachment, further having a linear or branched, cyclo, cyclic or acyclic structure, further having at least one atom, in addition to the oxygen of the carbonyl group, independently selected from the group consisting of N, O, F, Cl, Br, I, Si, P, and S.
• substituted acyl encompasses, but is not limited to, "hexyl,
• alkoxy when used without the "substituted” modifier refers to the group -OR, in which R is an alkyl, as that term is defined above.
• alkoxy groups include: -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 CH 3 , -OCH(CH 3 ) 2 , -OCH(CH 2 ) 2 , -O-cyclopentyl, and -O-cyclohexyl.
• substituted alkoxy refers to the group -OR, in which R is a substituted alkyl, as that term is defined above. For example, -OCH 2 CF 3 is a substituted alkoxy group.
• alkenyloxy when used without the “substituted” modifier, refers to groups, defined as -OR, in which R is alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl and acyl, respectively, as those terms are defined above.
• Non-limiting examples of alkylamino groups include: -NHCH 3 , -NHCH 2 CH 3 , -NHCH 2 CH 2 CH 3 , -NHCH(CH 3 ) 2 , -NHCH(CH 2 ) 2 , -NHCH 2 CH 2 CH 2 CH 3 , -NHCH(CH 3 )CH 2 CH 3 , -NHCH 2 CH(CH 3 ) 2 , -NHC(CH 3 ) 3 , -NH-cyclopentyl, and -NH-cyclohexyl.
• substituted alkylamino refers to the group -NHR, in which R is a substituted alkyl, as that term is defined above.
• -NHCH2CF3 is a substituted alkylamino group.
• dialkylamino when used without the "substituted” modifier refers to the group -NRR', in which R and R' can be the same or different alkyl groups, or R and R' can be taken together to represent an alkanediyl having two or more saturated carbon atoms, at least two of which are attached to the nitrogen atom.
• Non-limiting examples of dialkylamino groups include: -NHC(CH 3 ) 3 , -N(CH 3 )CH 2 CH 3 , -N(CH 2 CH 3 ) 2 , N-pyrrolidinyl, and N- piperidinyl.
• alkoxyamino refers to groups, defined as -NHR, in which R is alkoxy, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl and alkylsulfonyl, respectively, as those terms are defined above.
• R is alkoxy, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl and alkylsulfonyl, respectively, as those terms are defined above.
• a non-limiting example of an arylamino group is -NHC6H5.
• alkoxyamino, alkenylamino, alkynylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino and alkylsulfonylamino is modified by "substituted,” it refers to the group -NHR, in which R is substituted alkoxy, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl and alkylsulfonyl, respectively.
• NCH 2 CF 3 is a substituted alkylimino group.
• substituted fluoroalkyl refers to a non-aromatic monovalent group with a saturated carbon atom as the point of attachment, a linear or branched, cyclo, cyclic or acyclic structure, at least one fluorine atom, no carbon-carbon double or triple bonds, and at least one atom independently selected from the group consisting of N, O, Cl, Br, I, Si, P, and S.
• the following group is a non- limiting example of a substituted fluoroalkyl: -CFHOH.
• alkylthio when used without the "substituted” modifier refers to the group -SR, in which R is an alkyl, as that term is defined above.
• alkylthio groups include: -SCH 3 , -SCH 2 CH 3 , -SCH 2 CH 2 CH 3 , -SCH(CH 3 ) 2 , -SCH(CH 2 ) 2 , -S-cyclopentyl, and -S-cyclohexyl.
• substituted alkylthio refers to the group -SR, in which R is a substituted alkyl, as that term is defined above.
• -SCH 2 CF 3 is a substituted alkylthio group.
• alkenylthio when used without the “substituted” modifier, refers to groups, defined as -SR, in which R is alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl and acyl, respectively, as those terms are defined above.
• alkenylthio, alkynylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, and acylthio is modified by "substituted,” it refers to the group -SR, in which R is substituted alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl and acyl, respectively.
• alkylsulfonyl when used without the “substituted” modifier refers to the group -S(O) 2 R, in which R is an alkyl, as that term is defined above.
• alkylsulfonyl groups include: -S(O) 2 CH 3 , -S(O) 2 CH 2 CH 3 , -S(O) 2 CH 2 CH 2 CH 3 ,
• alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, aralkylsulfonyl, heteroarylsulfonyl, and heteroaralkylsulfonyl is modified by "substituted,” it refers to the group -S(O) 2 R, in which R is substituted alkenyl, alkynyl, aryl, aralkyl, heteroaryl and heteroaralkyl, respectively.
• alkylammonium when used without the "substituted” modifier refers to a group, defined as -NH 2 R + , -NHRR' + , or -NRR'R” + , in which R, R' and R" are the same or different alkyl groups, or any combination of two of R, R' and R" can be taken together to represent an alkanediyl.
• substituted alkylammonium refers -NH 2 R + , -NHRRZ + , or -NRR'R" + , in which at least one of R, R' and R" is a substituted alkyl or two of R, R' and R" can be taken together to represent a substituted alkanediyl. When more than one of R, R' and R" is a substituted alkyl, they can be the same of different.
• R, R' and R" that are not either substituted alkyl or substituted alkanediyl can be either alkyl, either the same or different, or can be taken together to represent a alkanediyl with two or more carbon atoms, at least two of which are attached to the nitrogen atom shown in the formula.
• alkylsulfonium when used without the "substituted” modifier refers to the group -SRR ' + , in which R and R' can be the same or different alkyl groups, or R and R' can be taken together to represent an alkanediyl.
• Non-limiting examples of alkylsulfonium groups include: -SH(CH 3 ) + , -SH(CH 2 CH 3 ) + , -SH(CH 2 CH 2 CH 3 ) + , -S(CH 3 ) 2 + , -S(CH 2 CH 3 ) 2 + , -S(CH 2 CH 2 CH 3 ) 2 + , -SH(cyclopentyl) + , and -SH(cyclohexyl) + .
• substituted alkylsilyl refers -SiH 2 R, -SiHRR', or -SiRR'R", in which at least one of R, R' and R" is a substituted alkyl or two of R, R' and R" can be taken together to represent a substituted alkanediyl. When more than one of R, R' and R" is a substituted alkyl, they can be the same of different.
• R, R' and R" that are not either substituted alkyl or substituted alkanediyl can be either alkyl, either the same or different, or can be taken together to represent a alkanediyl with two or more saturated carbon atoms, at least two of which are attached to the silicon atom.
• the structure includes the structures and As will be understood by a person of skill in the art, no one such ring atom forms part of more than one double bond.
• a ring structure shown with an unconnected "R" group indicates that any implicit hydrogen atom on that ring can be replaced with that R group.
• R group e.g., oxo, imino, thio, alkylidene, etc.
• any pair of implicit hydrogen atoms attached to one atom of that ring can be replaced by that R group.
• a "chiral auxiliary” refers to a removable chiral group that is capable of influencing the stereoselectivity of a reaction. Persons of skill in the art are familiar with such compounds, and many are commercially available.
• hydrate when used as a modifier to a compound means that the compound has less than one (e.g., hemihydrate), one (e.g., monohydrate), or more than one (e.g., dihydrate) water molecules associated with each compound molecule, such as in solid forms of the compound.
• IC50 refers to an inhibitory dose which is 50% of the maximum response obtained.
• An "isomer" of a first compound is a separate compound in which each molecule contains the same constituent atoms as the first compound, but where the configuration of those atoms in three dimensions differs.
• “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.
• “Pharmaceutically acceptable salts” means salts of compounds of the present disclosure which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as 1 ,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, 2-naphthalenesulfonic acid, 3-phenylpropionic acid,
• progenitantly one enantiomer means that a compound contains at least about 85% of one enantiomer, or more preferably at least about 90% of one enantiomer, or even more preferably at least about 95% of one enantiomer, or most preferably at least about 99% of one enantiomer.
• Prevention includes: (1) inhibiting the onset of a disease in a subject or patient which may be at risk and/or predisposed to the disease but does not yet experience or display any or all of the pathology or symptomatology of the disease, and/or (2) slowing the onset of the pathology or symptomatology of a disease in a subject or patient which may be at risk and/or predisposed to the disease but does not yet experience or display any or all of the pathology or symptomatology of the disease.
• Prodrug means a compound that is convertible in vivo metabolically into an inhibitor according to the present disclosure.
• the prodrug itself may or may not also have activity with respect to a given target protein.
• a compound comprising a hydroxy group may be administered as an ester that is converted by hydrolysis in vivo to the hydroxy compound.
• esters that may be converted in vivo into hydroxy compounds include acetates, citrates, lactates, phosphates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- ⁇ -hydroxynaphthoate, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, /?-toluenesulfonates, cyclohexylsulfamates, quinates, esters of amino acids, and the like.
• a compound comprising an amine group may be administered as an amide that is converted by hydrolysis in vivo to the amine compound.
• saturated when referring to an atom means that the atom is connected to other atoms only by means of single bonds.
• a “stereoisomer” or “optical isomer” is an isomer of a given compound in which the same atoms are bonded to the same other atoms, but where the configuration of those atoms in three dimensions differs.
• “Enantiomers” are stereoisomers of a given compound that are mirror images of each other, like left and right hands.
• Diastereomers are stereoisomers of a given compound that are not enantiomers.
• stereocenter or axis of chirality for which stereochemistry has not been defined, that stereocenter or axis of chirality can be present in its R form, S form, or as a mixture of the R and S forms, including racemic and non-racemic mixtures.
• suitable amino acid residues also include amino acid residues that are protected with a protecting group.
• suitable protecting groups include those typically employed in peptide synthesis, including acyl groups (such as formyl and acetyl), arylmethyloxycarbonyl groups (such as benzyloxycarbonyl and p-nitrobenzyloxycarbonyl), tert-butoxycarbonyl groups (-C(O)OC(CH3)3), and the like.
• Suitable peptide residues include peptide residues comprising two to five, and optionally amino acid residues. The residues of these amino acids or peptides can be present in stereochemical configurations of the D-form, the L-form or mixtures thereof.
• water soluble means that the compound dissolves in water at least to the extent of 0.010 mole/liter or is classified as soluble according to literature precedence.
• DMSO dimethyl sulfoxide
• NO nitric oxide
• iNOS inducible nitric oxide synthase
• COX-2 cyclooxygenase-2
• NGF nerve growth factor
• IBMX isobutylmethylxanthine
• FBS fetal bovine serum
• GPDH glycerol 3- phosphate dehydrogenase
• RXR retinoid X receptor
• TGF- ⁇ transforming growth factor- ⁇
• IFN ⁇ or IFN- ⁇ interferon- ⁇
• LPS bacterial endotoxic lipopolysaccharide
• TNF ⁇ or TNF- ⁇ tumor necrosis factor- ⁇
• IL- l ⁇ interleukin-l ⁇
• GAPDH glyceride-1
• Biological activity results are provided throughout the present disclosure. These include: inhibition of inhibition of NO production, iNOS induction, Nrf2 target gene induction, inhibition of COX-2 induction, inhibition of STAT3 phosphorylation, suppression of IL-6 induced phosphorylation, inhibition of TNF ⁇ -induced I ⁇ B ⁇ degradation, inhibition of NF -KB activation, induction of HO-I, induction of TrxRl, induction of ⁇ -GCS, and/or induction of ferritin heavy chain. See figures and figure descriptions. Suppression of NO production and induction of Nrf2 induction results can be respectively summarized as shown Tables Ia and Ib, below. Further results, including toxicity studies, are provided in the Examples section. Table Ia. Su ression of IFN ⁇ -Induced NO Production.
• Dysregulation of inflammatory signaling pathways is believed to be a major factor in the pathology of muscle wasting diseases including muscular dystrophy and various forms of cachexia.
• a variety of life -threatening acute disorders also involve dysregulated inflammatory signaling, including acute organ failure involving the pancreas, kidneys, liver, or lungs, myocardial infarction or acute coronary syndrome, stroke, septic shock, trauma, severe burns, and anaphylaxis.
• inflammatory responses can kill invading pathogens
• an excessive inflammatory response can also be quite destructive and in some cases can be a primary source of damage in infected tissues.
• an excessive inflammatory response can also lead to systemic complications due to overproduction of inflammatory cytokines such as TNF- ⁇ and IL-I. This is believed to be a factor in mortality arising from severe influenza, severe acute respiratory syndrome, and sepsis.
• a series of synthetic triterpenoid analogs of oleanolic acid have been shown to be powerful inhibitors of cellular inflammatory processes, such as the induction by IFN- ⁇ of inducible nitric oxide synthase (iNOS) and of COX-2 in mouse macrophages. See Honda et al. (2000a); Hyundai et al. (2000b), and Honda et al. (2002), which are all incorporated herein by reference.
• iNOS inducible nitric oxide synthase
• oxidative stress and dysregulation of inflammatory processes including cancer, mucositis resulting from radiation therapy or chemotherapy, autoimmune diseases, cardiovascular diseases including atherosclerosis, ischemia-reperfusion injury, acute and chronic organ failure including renal failure and heart failure, respiratory diseases, diabetes and complications of diabetes, severe allergies, transplant rejection, graft- versus-host disease, neurodegenerative diseases, diseases of the eye and retina, acute and chronic pain, degenerative bone diseases including osteoarthritis and osteoporosis, inflammatory bowel diseases, dermatitis and other skin diseases, sepsis, burns, seizure disorders, and neuropsychiatric disorders.
• heme oxygenase a target gene of the Nrf2 pathway
• This enzyme breaks free heme down into iron, carbon monoxide (CO), and biliverdin (which is subsequently converted to the potent antioxidant molecule, bilirubin).
• compounds of this invention may be used in preventing or treating tissue damage or organ failure, acute and chronic, resulting from oxidative stress exacerbated by inflammation.
• diseases that fall in this category include: heart failure, liver failure, transplant failure and rejection, renal failure, pancreatitis, fibrotic lung diseases (cystic fibrosis and COPD, among others), diabetes (including complications), atherosclerosis, ischemia-reperfusion injury, glaucoma, stroke, autoimmune disease, autism, macular degeneration, and muscular dystrophy.
• diseases include: heart failure, liver failure, transplant failure and rejection, renal failure, pancreatitis, fibrotic lung diseases (cystic fibrosis and COPD, among others), diabetes (including complications), atherosclerosis, ischemia-reperfusion injury, glaucoma, stroke, autoimmune disease, autism, macular degeneration, and muscular dystrophy.
• autism studies suggest that increased oxidative stress in the central nervous system may contribute to the development of the disease (Chauhan and Chauhan, 2006).
• Evidence also links oxidative stress and inflammation to the development and pathology of many other disorders of the central nervous system, including psychiatric disorders such as psychosis, major depression, and bipolar disorder; seizure disorders such as epilepsy; pain and sensory syndromes such as migraine, neuropathic pain or tinnitus; and behavioral syndromes such as the attention deficit disorders.
• psychiatric disorders such as psychosis, major depression, and bipolar disorder
• seizure disorders such as epilepsy
• pain and sensory syndromes such as migraine, neuropathic pain or tinnitus
• behavioral syndromes such as the attention deficit disorders.
• the compounds of the invention may be used to function as antioxidant inflammation modulators (AIMs) having potent anti-inflammatory properties that mimic the biological activity of cyclopentenone prostaglandins (cyPGs).
• AIMs antioxidant inflammation modulators
• the compounds of the invention may be used to control the production of pro-inflammatory cytokines by selectively targeting regulatory cysteine residues (RCRs) on proteins that regulate the transcriptional activity of redox-sensitive transcription factors.
• RCRs regulatory cysteine residues
• Activation of RCRs by cyPGs or AIMs has been shown to initiate a pro-resolution program in which the activity of the antioxidant and cytoprotective transcription factor Nrf2 is potently induced, and the activities of the pro-oxidant and pro-inflammatory transcription factors NF- ⁇ B and the STATs are suppressed.
• antioxidant and reductive molecules e.g., NQOl, HO-I, SODl, and/or ⁇ -GCS
• pro-oxidant and pro-inflammatory molecules e.g., iNOS, COX-2, and/or TNF- ⁇
• Another aspect of inflammation is the production of inflammatory prostaglandins such as prostaglandin E.
• These molecules promote vasodilation, plasma extravasation, localized pain, elevated temperature, and other symptoms of inflammation.
• the inducible form of the enzyme COX-2 is associated with their production, and high levels of COX-2 are found in inflamed tissues. Consequently, inhibition of COX-2 may relieve many symptoms of inflammation and a number of important anti -inflammatory drugs (e.g., ibuprofen and celecoxib) act by inhibiting COX-2 activity.
• ibuprofen and celecoxib important anti -inflammatory drugs
• the compounds of the invention may be used to control the production of pro-inflammatory cytokines within the cell by selectively activating regulatory cysteine residues (RCRs) on proteins that regulate the activity of redox-sensitive transcription factors.
• RCRs regulatory cysteine residues
• Activation of RCRs by cyPGs has been shown to initiate a pro-resolution program in which the activity of the antioxidant and cytoprotective transcription factor Nrf2 is potently induced and the activities of the pro-oxidant and pro-inflammatory transcription factors NF- ⁇ B and the STATs are suppressed.
• this increases the production of antioxidant and reductive molecules (NQOl, HO-I, SODl, ⁇ -GCS) and decreases oxidative stress and the production of pro-oxidant and pro-inflammatory molecules (iNOS, COX-2, TNF- ⁇ ).
• the compounds of this invention may cause the cells that host the inflammatory event to revert to a non-inflammatory state by promoting the resolution of inflammation and limiting excessive tissue damage to the host.
• Arginase and iNOS are enzymes that utilize L- arginine as a substrate and produce L-ornithine and urea, and L-citrulline and NO, respectively.
• the depletion of arginine from the tumor microenvironment by MDSCs, combined with the production of NO and peroxynitrite has been shown to inhibit proliferation and induce apoptosis of T cells (Bronte et al, 2003).
• Inhibition of COX-2 and iNOS has been shown to reduce the accumulation of MDSCs, restore cytotoxic activity of tumor- associated T cells, and delay tumor growth (Sinha et al, 2007; Mazzoni et al, 2002; Zhou et al, 2007).
• NF- ⁇ B and STAT3 also have important roles in other cells found within the tumor microenvironment.
• NF- ⁇ B is required in both cancer cells and hematopoeitic cells to propagate the effects of inflammation on cancer initiation and progression (Greten et al, 2004).
• NF -KB inhibition in cancer and myeloid cells reduces the number and size, respectively, of the resultant tumors.
• Activation of STAT3 in cancer cells results in the production of several cytokines (IL-6, IL-10) which suppress the maturation of tumor-associated dendritic cells (DC).
• DC tumor-associated dendritic cells
• STAT3 is activated by these cytokines in the dendritic cells themselves. Inhibition of STAT3 in mouse models of cancer restores DC maturation, promotes antitumor immunity, and inhibits tumor growth (Kortylewski et al, 2005).
• MS multiple sclerosis
• AD Alzheimer's disease
• PD Parkinson's disease
• ALS amyotrophic lateral sclerosis
• MS Bagasra et al, 1995; McGeer and McGeer, 1995; Simonian and Coyle, 1996; Kaltschmidt et al, 1997).
• NDD neurodegenerative disease
• NID neuroinflammatory disease
• iNOS neuroinflammatory disease
• COX-2 neuroinflammatory cytokines
• agents that block formation of NO and prostaglandins may be used in approaches to prevention and treatment of NDD.
• Successful therapeutic candidates for treating such a disease typically require an ability to penetrate the blood-brain barrier. See, for example, U.S. Patent Publication 2009/0060873, which is incorporated by reference herein in its entirety.
• the compounds and methods of this invention may be used for treating patients with neuroinflammation.
• Neuroinflammation encapsulates the idea that microglial and astrocytic responses and actions in the central nervous system have a fundamentally inflammation-like character, and that these responses are central to the pathogenesis and progression of a wide variety of neurological disorders. This idea originated in the field of Alzheimer's disease (Griffin et al, 1989; Rogers et al, 1988), where it has revolutionized our understanding of this disease (Akiyama et al, 2000).
• Neuroinflammation incorporates a wide spectrum of complex cellular responses that include activation of microglia and astrocytes and induction of cytokines, chemokines, complement proteins, acute phase proteins, oxidative injury, and related molecular processes.
• neuronal function leading to neuronal injury, further glial activation, and ultimately neurodegeneration.
• Acute renal failure may arise from exposure to certain drugs (e.g., acetaminophen) or toxic chemicals, or from ischemia- reperfusion injury associated with shock or surgical procedures such as transplantation, and may result in chronic renal failure.
• drugs e.g., acetaminophen
• ischemia- reperfusion injury associated with shock or surgical procedures such as transplantation
• renal failure advances to a stage in which the patient requires regular dialysis or kidney transplantation to continue living. Both of these procedures are highly invasive and associated with significant side effects and quality of life issues.
• hyperparathyroidism and hyperphosphatemia no available treatment has been shown to halt or reverse the underlying progression of renal failure.
• agents that can improve compromised renal function would represent a significant advance in the treatment of renal failure.
• CKD CKD-induced oxidative stress
• MCP-I a chemokine that is responsible for the recruitment of monocytes/macrophages resulting in an inflammatory response that ultimately injures the kidney
• the Keapl/Nrf2/ARE pathway controls the transcription of several genes encoding antioxidant enzymes, including heme oxygenase- 1 (HO-I).
• Nrf2 Nrf2 Reduction of the Nrf2 gene in female mice results in the development of lupus-like glomerular nephritis (Yoh et ah, 2001). Furthermore, several studies have demonstrated that HO-I expression is induced in response to renal damage and inflammation and that this enzyme and its products - bilirubin and carbon monoxide - play a protective role in the kidney (Nath et ah, 2006).
• GFR Glomerular filtration rate
• Creatinine clearance is commonly used to measure GFR.
• the level of serum creatinine is commonly used as a surrogate measure of creatinine clearance. For instance, excessive levels of serum creatinine are generally accepted to indicate inadequate renal function and reductions in serum creatinine over time are accepted as an indication of improved renal function.
• Normal levels of creatinine in the blood are approximately 0.6 to 1.2 milligrams (mg) per deciliter (dl) in adult males and 0.5 to 1.1 milligrams per deciliter in adult females.
• Acute kidney injury can occur following ischemia-rep erfusion, treatment with certain pharmacological agents such as cisplatin and rapamycin, and intravenous injection of radiocontrast media used in medical imaging.
• inflammation and oxidative stress contribute to the pathology of AKI.
• the molecular mechanisms underlying radiocontrast- induced nephropathy (RCN) are not well understood; however, it is likely that a combination of events including prolonged vasoconstriction, impaired kidney autoregulation, and direct toxicity of the contrast media all contribute to renal failure (Tumlin et ah, 2006).
• Vasoconstriction results in decreased renal blood flow and causes ischemia-reperfusion and the production of reactive oxygen species.
• CV disease cardiovascular disease
• the compounds and methods of this invention may be used for treating patients with cardiovascular disease. See U.S. Patent Application 12/352,473, which is incorporated by reference herein in its entirety.
• Cardiovascular (CV) disease is among the most important causes of mortality worldwide, and is the leading cause of death in many developed countries.
• the etiology of CV disease is complex, but the majority of causes are related to inadequate or completely disrupted supply of blood to a critical organ or tissue. Frequently such a condition arises from the rupture of one or more atherosclerotic plaques, which leads to the formation of a thrombus that blocks blood flow in a critical vessel.
• Such thrombosis is the principal cause of heart attacks, in which one or more of the coronary arteries is blocked and blood flow to the heart itself is disrupted.
• ischemia- reperfusion injury a phenomenon known as ischemia- reperfusion injury.
• Similar damage occurs in the brain during a thrombotic stroke, when a cerebral artery or other major vessel is blocked by thrombosis.
• Hemorrhagic strokes in contrast, involve rupture of a blood vessel and bleeding into the surrounding brain tissue. This creates oxidative stress in the immediate area of the hemorrhage, due to the presence of large amounts of free heme and other reactive species, and ischemia in other parts of the brain due to compromised blood flow.
• Subarachnoid hemorrhage which is frequently accompanied by cerebral vasospasm, also causes ischemia/reperfusion injury in the brain.
• Atherosclerosis may be so extensive in critical blood vessels that stenosis (narrowing of the arteries) develops and blood flow to critical organs (including the heart) is chronically insufficient.
• stenosis narrowing of the arteries
• critical organs including the heart
• chronic ischemia can lead to end-organ damage of many kinds, including the cardiac hypertrophy associated with congestive heart failure.
• Atherosclerosis the underlying defect leading to many forms of cardiovascular disease, occurs when a physical defect or injury to the lining (endothelium) of an artery triggers an inflammatory response involving the proliferation of vascular smooth muscle cells and the infiltration of leukocytes into the affected area.
• a complicated lesion known as an atherosclerotic plaque may form, composed of the above-mentioned cells combined with deposits of cholesterol-bearing lipoproteins and other materials (e.g., Hansson et al, 2006).
• cardiovascular disease treatments for cardiovascular disease include preventive treatments, such as the use of drugs intended to lower blood pressure or circulating levels of cholesterol and lipoproteins, as well as treatments designed to reduce the adherent tendencies of platelets and other blood cells (thereby reducing the rate of plaque progression and the risk of thrombus formation). More recently, drugs such as streptokinase and tissue plasminogen activator have been introduced and are used to dissolve the thrombus and restore blood flow.
• Surgical treatments include coronary artery bypass grafting to create an alternative blood supply, balloon angioplasty to compress plaque tissue and increase the diameter of the arterial lumen, and carotid endarterectomy to remove plaque tissue in the carotid artery.
• Such treatments may be accompanied by the use of stents, expandable mesh tubes designed to support the artery walls in the affected area and keep the vessel open.
• drug-eluting stents has become common in order to prevent post-surgical restenosis (renarrowing of the artery) in the affected area.
• These devices are wire stents coated with a biocompatible polymer matrix containing a drug that inhibits cell proliferation (e.g., paclitaxel or rapamycin). The polymer allows a slow, localized release of the drug in the affected area with minimal exposure of non-target tissues.
• Diabetes is a complex disease characterized by the body's failure to regulate circulating levels of glucose. This failure may result from a lack of insulin, a peptide hormone that regulates both the production and absorption of glucose in various tissues. Deficient insulin compromises the ability of muscle, fat, and other tissues to absorb glucose properly, leading to hyperglycemia (abnormally high levels of glucose in the blood). Most commonly, such insulin deficiency results from inadequate production in the islet cells of the pancreas.
• Type 1 diabetes a condition known as type 1 or juvenile -onset diabetes, but may also be due to physical trauma or some other cause. Diabetes may also arise when muscle and fat cells become less responsive to insulin and do not absorb glucose properly, resulting in hyperglycemia. This phenomenon is known as insulin resistance, and the resulting condition is known as Type 2 diabetes. Type 2 diabetes, the most common type, is highly associated with obesity and hypertension. Obesity is associated with an inflammatory state of adipose tissue that is thought to play a major role in the development of insulin resistance (e.g., Hotamisligil, 2006; Guilherme et al., 2008).
• Diabetes is associated with damage to many tissues, largely because hyperglycemia (and hypoglycemia, which can result from excessive or poorly timed doses of insulin) is a significant source of oxidative stress.
• Chronic kidney failure, retinopathy, peripheral neuropathy, peripheral vasculitis, and the development of dermal ulcers that heal slowly or not at all are among the common complications of diabetes.
• compounds of the invention may be used in treatments for many complications of diabetes.
• chronic inflammation and oxidative stress in the liver are suspected to be primary contributing factors in the development of Type 2 diabetes.
• PPAR ⁇ agonists such as thiazolidinediones are capable of reducing insulin resistance and are known to be effective treatments for Type 2 diabetes.
• the effect of treatment of diabetes may be evaluated as follows. Both the biological efficacy of the treatment modality as well as the clinical efficacy are evaluated, if possible. For example, because the disease manifests itself by increased blood sugar, the biological efficacy of the treatment therefore can be evaluated, for example, by observation of return of the evaluated blood glucose towards normal. Measurement of glycosylated hemoglobin, also called AIc or HbAIc, is another commonly used parameter of blood glucose control. Measuring a clinical endpoint which can give an indication of b-cell regeneration after, for example, a six -month period of time, can give an indication of the clinical efficacy of the treatment regimen.
• AIc glycosylated hemoglobin
• the compounds and methods of this invention may be used for treating patients with RA.
• RA rheumatoid arthritis
• the first signs of rheumatoid arthritis (RA) appear in the synovial lining layer, with proliferation of synovial fibroblasts and their attachment to the articular surface at the joint margin (Lipsky, 1998).
• macrophages, T cells and other inflammatory cells are recruited into the joint, where they produce a number of mediators, including the cytokines interleukin-1 (IL-I), which contributes to the chronic sequelae leading to bone and cartilage destruction, and tumour necrosis factor (TNF- ⁇ ), which plays a role in inflammation
• IL-I interleukin-1
• TNF- ⁇ tumour necrosis factor
• IL-I concentration of IL-I in plasma is significantly higher in patients with RA than in healthy individuals and, notably, plasma IL-I levels correlate with RA disease activity (Eastgate et al., 1988). Moreover, synovial fluid levels of IL-I are correlated with various radiographic and histologic features of RA (Kahle et al, 1992; Rooney et al, 1990).
• IL- Ira is a natural receptor antagonist that competes with IL-I for binding to type I IL-I receptors and, as a result, blocks the effects of IL-I (Arend et al, 1998). A 10- to 100-fold excess of IL- Ira may be needed to block IL-I effectively; however, synovial cells isolated from patients with RA do not appear to produce enough IL- Ira to counteract the effects of IL-I (Firestein et al, 1994; Fujikawa et al, 1995). H. Psoriatic Arthritis
• PsA belongs to the SpA group has recently gained further support from imaging studies demonstrating widespread enthesitis in the, including PsA but not RA (McGonagle et al, 1999; McGonagle et al, 1998). More specifically, enthesitis has been postulated to be one of the earliest events occurring in the SpAs, leading to bone remodeling and ankylosis in the spine, as well as to articular synovitis when the inflamed entheses are close to peripheral joints.
• the compounds and methods of this invention may be used for treating patients with reactive arthritis.
• reactive arthritis ReA
• the mechanism of joint damage is unclear, but it is likely that cytokines play critical roles.
• IFN- ⁇ interferon gamma
• IL-4 interleukin 4
• SF fluid
• IL-IO is a regulatory cytokine that inhibits the synthesis of IL- 12 and TNF- ⁇ by activated macrophages (de Waal et al, 1991; Hart et al, 1995; Chomarat et al, 1995) and of IFN- ⁇ by T cells (Macatonia et al, 1993). J. Enteropathic Arthritis
• enteropathic arthritis occurs in combination with inflammatory bowel diseases (IBD) such as Crohn's disease or ulcerative colitis. It also can affect the spine and sacroiliac joints.
• IBD inflammatory bowel diseases
• Enteropathic arthritis involves the peripheral joints, usually in the lower extremities such as the knees or ankles. It commonly involves only a few or a limited number of joints and may closely follow the bowel condition. This occurs in approximately 11% of patients with ulcerative colitis and 21% of those with Crohn's disease.
• the synovitis is generally self-limited and non-deforming.
• JRA Juvenile rheumatoid arthritis
• JRA This subtype of JRA may be severe, because of both its multiple joint involvement and its capacity to progress rapidly over time.
• polyarticular JRA is not homogeneous, and patients vary in disease manifestations, age of onset, prognosis, and therapeutic response. These differences very likely reflect a spectrum of variation in the nature of the immune and inflammatory attack that can occur in this disease (Jarvis, 1998).
• the compounds and methods of this invention may be used for treating patients with early inflammatory arthritis.
• the clinical presentation of different inflammatory arthropathies is similar early in the course of disease. As a result, it is often difficult to distinguish patients who are at risk of developing the severe and persistent synovitis that leads to erosive joint damage from those whose arthritis is more self-limited. Such distinction is critical in order to target therapy appropriately, treating aggressively those with erosive disease and avoiding unnecessary toxicity in patients with more self-limited disease.
• Current clinical criteria for diagnosing erosive arthropathies such as rheumatoid arthritis (RA) are less effective in early disease and traditional markers of disease activity such as joint counts and acute phase response do not adequately identify patients likely to have poor outcomes (Harrison et al,
• anti-CCP antibodies are often detectable in sera many years prior to clinical symptoms suggesting that they may be reflective of subclinical immune events (Nielen et al., 2004; Rantapaa-Dahlqvist et al., 2003).
• Ankylosing Spondylitis The compounds and methods of this invention may be used for treating patients with ankylosing spondylitis.
• AS is a disease subset within a broader disease classification of spondyloarthropathy. Patients affected with the various subsets of spondyloarthropathy have disease etiologies that are often very different, ranging from bacterial infections to inheritance. Yet, in all subgroups, the end result of the disease process is axial arthritis. Despite the early clinically differences seen in the various patient populations, many of them end up nearly identical after a disease course of ten-to-twenty years. Recent studies suggest the mean time to clinical diagnosis of ankylosing spondylitis from disease onset of disease is 7.5 years (Khan, 1998).
• AS is a chronic systemic inflammatory rheumatic disorder of the axial skeleton with or without extraskeletal manifestations. Sacroiliac joints and the spine are primarily affected, but hip and shoulder joints, and less commonly peripheral joints or certain extra-articular structures such as the eye, vasculature, nervous system, and gastrointestinal system may also be involved. Its etiology is not yet fully understood (Wordsworth, 1995; Calin and Taurog, 1998).
• MHC I major histocompatibility class I HLA-B27 allele
• AS affects individuals in the prime of their life and is feared because of its potential to cause chronic pain and irreversible damage of tendons, ligaments, joints, and bones (Brewerton et al., 1973a; Brewerton et al., 1973b; Schlosstein et al., 1973).
• AS may occur alone or in association with another form of spondyloarthropathy such as reactive arthritis, psoriasis, psoriatic arthritis, enthesitis, ulcerative colitis, irritable bowel disease, or Crohn's disease, in which case it is classified as secondary AS.
• the affected sites include the discovertebral, apophyseal, costovertebral, and costotransverse joints of the spine, and the paravertebral ligamentous structures.
• Inflammation of the entheses which are sites of musculotendinous and ligamentous attachment to bones, is also prominent in this disease (Calin and Taurog, 1998).
• the site of enthesitis is known to be infiltrated by plasma cells, lymphocytes, and polymorphonuclear cells. The inflammatory process frequently results in gradual fibrous and bony ankylosis, (Ball, 1971; Khan, 1990).
• AS is characterized by mild or moderate flares of active spondylitis alternating with periods of almost or totally inactive inflammation. Proper treatment in most patients results in minimal or no disability and in full, productive lives despite back stiffness. Occasionally, the course is severe and progressive, resulting in pronounced incapacitating deformities. The prognosis is bleak for patients with refractory ulceris and for the rare patient with secondary amyloidosis. N. Ulcerative Colitis
• Ulcerative colitis is a disease that causes inflammation and sores, called ulcers, in the lining of the large intestine.
• the inflammation usually occurs in the rectum and lower part of the colon, but it may affect the entire colon.
• Ulcerative colitis rarely affects the small intestine except for the end section, called the terminal ileum. Ulcerative colitis may also be called colitis or proctitis.
• the inflammation makes the colon empty frequently, causing diarrhea. Ulcers form in places where the inflammation has killed the cells lining the colon; the ulcers bleed and produce pus.
• Ulcerative colitis is an inflammatory bowel disease (IBD), the general name for diseases that cause inflammation in the small intestine and colon.
• IBD inflammatory bowel disease
• Ulcerative colitis can be difficult to diagnose because its symptoms are similar to other intestinal disorders and to another type of IBD, Crohn's disease. Crohn's disease differs from ulcerative colitis because it causes inflammation deeper within the intestinal wall. Also, Crohn's disease usually occurs in the small intestine, although it can also occur in the mouth, esophagus, stomach, duodenum, large intestine, appendix, and anus.
• Ulcerative colitis may occur in people of any age, but most often it starts between ages 15 and 30, or less frequently between ages 50 and 70. Children and adolescents sometimes develop the disease. Ulcerative colitis affects men and women equally and appears to run in some families.
• ulcerative colitis The most common symptoms of ulcerative colitis are abdominal pain and bloody diarrhea. Patients also may experience fatigue, weight loss, loss of appetite, rectal bleeding, and loss of body fluids and nutrients. About half of patients have mild symptoms. Others suffer frequent fever, bloody diarrhea, nausea, and severe abdominal cramps. Ulcerative colitis may also cause problems such as arthritis, inflammation of the eye, liver disease (hepatitis, cirrhosis, and primary sclerosing cholangitis), osteoporosis, skin rashes, and anemia. No one knows for sure why problems occur outside the colon. Peoples think these complications may occur when the immune system triggers inflammation in other parts of the body. Some of these problems go away when the colitis is treated.
• a thorough physical exam and a series of tests may be required to diagnose ulcerative colitis.
• Blood tests may be done to check for anemia, which could indicate bleeding in the colon or rectum. Blood tests may also uncover a high white blood cell count, which is a sign of inflammation somewhere in the body.
• the doctor can detect bleeding or infection in the colon or rectum. The doctor may do a colonoscopy or sigmoidoscopy. For either test, the doctor inserts an endoscope - a long, flexible, lighted tube connected to a computer and TV monitor - into the anus to see the inside of the colon and rectum. The doctor will be able to see any inflammation, bleeding, or ulcers on the colon wall.
• the doctor may do a biopsy, which involves taking a sample of tissue from the lining of the colon to view with a microscope.
• a barium enema x ray of the colon may also be required. This procedure involves filling the colon with barium, a chalky white solution. The barium shows up white on x-ray film, allowing the doctor a clear view of the colon, including any ulcers or other abnormalities that might be there.
• ulcerative colitis Treatment for ulcerative colitis depends on the seriousness of the disease. Most people are treated with medication. In severe cases, a patient may need surgery to remove the diseased colon. Surgery is the only cure for ulcerative colitis. Some people whose symptoms are triggered by certain foods are able to control the symptoms by avoiding foods that upset their intestines, like highly seasoned foods, raw fruits and vegetables, or milk sugar (lactose). Each person may experience ulcerative colitis differently, so treatment is adjusted for each individual. Emotional and psychological support is important. Some people have remissions - periods when the symptoms go away - that last for months or even years. However, most patients' symptoms eventually return. This changing pattern of the disease means one cannot always tell when a treatment has helped. Some people with ulcerative colitis may need medical care for some time, with regular doctor visits to monitor the condition.
• the compounds and methods of this invention may be used for treating patients with Crohn's disease.
• Crohn's disease symptoms include intestinal inflammation and the development of intestinal stenosis and fistulas; neuropathy often accompanies these symptoms.
• Antiinflammatory drugs such as 5 -aminosalicylates (e.g., mesalamine) or corticosteroids, are typically prescribed, but are not always effective (reviewed in Botoman et al, 1998). Immunosuppression with cyclosporine is sometimes beneficial for patients resistant to or intolerant of corticosteroids (Brynskov et al., 1989).
• Cytokines are small secreted proteins or factors (5 to 20 kD) that have specific effects on cell- to-cell interactions, intercellular communication, or the behavior of other cells. Cytokines are produced by lymphocytes, especially T H I and T H 2 lymphocytes, monocytes, intestinal macrophages, granulocytes, epithelial cells, and fibroblasts (reviewed in Rogler and. Andus, 1998; Galley and Webster, 1996).
• cytokines are pro-inflammatory ⁇ e.g., TNF- ⁇ , IL- l( ⁇ and ⁇ ), IL-6, IL-8, IL-12, or leukemia inhibitory factor [LIF]); others are anti-inflammatory ⁇ e.g., IL-I receptor antagonist, IL-4, IL-IO, IL-I l, and TGF- ⁇ ).
• pro-inflammatory ⁇ e.g., TNF- ⁇ , IL- l( ⁇ and ⁇ ), IL-6, IL-8, IL-12, or leukemia inhibitory factor [LIF]
• anti-inflammatory ⁇ e.g., IL-I receptor antagonist, IL-4, IL-IO, IL-I l, and TGF- ⁇ .
• TNF- ⁇ and IL-6 are secreted into the blood circulation, and TNF- ⁇ , IL-I, IL-6, and IL-8 are produced in excess locally by mucosal cells ⁇ id.; Funakoshi et al., 1998).
• cytokines can have far-ranging effects on physiological systems including bone development, hematopoiesis, and liver, thyroid, and neuropsychiatric function.
• Treatments that have been proposed for Crohn's disease include the use of various cytokine antagonists ⁇ e.g., IL- Ira), inhibitors ⁇ e.g., of IL- l ⁇ converting enzyme and antioxidants) and anti-cytokine antibodies (Rogler and Andus, 1998; van Hogezand and Verspaget, 1998; Reimund et al., 1998; Lugering et al., 1998; McAlindon et al., 1998).
• monoclonal antibodies against TNF- ⁇ have been tried with some success in the treatment of Crohn's disease (Targan et al., 1997; Stack et al., 1997; van Dullemen et al., 1995).
• the compounds and methods of this invention may be used for treating patients with SLE.
• autoimmune diseases such as systemic lupus erythematosus.
• Systemic lupus erythematosus SLE
• SLE is an autoimmune rheumatic disease characterized by deposition in tissues of autoantibodies and immune complexes leading to tissue injury (Kotzin, 1996).
• autoimmune diseases such as MS and type 1 diabetes mellitus
• SLE potentially involves multiple organ systems directly, and its clinical manifestations are diverse and variable (reviewed by Kotzin and O'Dell, 1995). For example, some patients may demonstrate primarily skin rash and joint pain, show spontaneous remissions, and require little medication.
• IgG anti-dsDNA antibodies play a major role in the development of lupus glomerulonephritis (G N) (Hahn and Tsao, 1993; Ohnishi et al, 1994).
• IBS Irritable bowel syndrome
• IBS is a functional disorder characterized by abdominal pain and altered bowel habits. This syndrome may begin in young adulthood and can be associated with significant disability. This syndrome is not a homogeneous disorder. Rather, subtypes of IBS have been described on the basis of the predominant symptom—diarrhea, constipation, or pain. In the absence of "alarm" symptoms, such as fever, weight loss, and gastrointestinal bleeding, a limited workup is needed. Once a diagnosis of IBS is made, an integrated treatment approach can effectively reduce the severity of symptoms. IBS is a common disorder, although its prevalence rates have varied. In general, IBS affects about 15% of US adults and occurs about three times more often in women than in men (Jailwala et al, 2000).
• IBS accounts for between 2.4 million and 3.5 million visits to physicians each year. It not only is the most common condition seen by gastroenterologists but also is one of the most common gastrointestinal conditions seen by primary care physicians (Everhart et al, 1991; Sandler, 1990).
• Inflammatory cytokines may play a role.
• a survey of patients with a history of confirmed bacterial gastroenteritis (Neal et al., 1997), 25% reported persistent alteration of bowel habits. Persistence of symptoms may be due to psychological stress at the time of acute infection (Gwee et al., 1999).
• IBS may present with a range of symptoms.
• abdominal pain and altered bowel habits remain the primary features.
• Abdominal discomfort is often described as crampy in nature and located in the left lower quadrant, although the severity and location can differ greatly.
• Patients may report diarrhea, constipation, or alternating episodes of diarrhea and constipation.
• Diarrheal symptoms are typically described as small-volume, loose stools, and stool is sometimes accompanied by mucus discharge. Patients also may report bloating, fecal urgency, incomplete evacuation, and abdominal distention.
• Upper gastrointestinal symptoms such as gastroesophageal reflux, dyspepsia, or nausea, may also be present (Lynn and Friedman, 1993). Persistence of symptoms is not an indication for further testing; it is a characteristic of
• the compounds and methods of this invention may be used for treating patients with SS.
• Primary Sjogren's syndrome (SS) is a chronic, slowly progressive, systemic autoimmune disease, which affects predominantly middle-aged women (female-to-male ratio 9:1), although it can be seen in all ages including childhood (Jonsson et al., 2002). It is characterized by lymphocytic infiltration and destruction of the exocrine glands, which are infiltrated by mononuclear cells including CD4+, CD8+ lymphocytes and B-cells (Jonsson et al., 2002). In addition, extraglandular (systemic) manifestations are seen in one-third of patients (Jonsson et al., 2001).
• ectopic lymphoid microstructures in the salivary glands (denoted as ectopic germinal centers) (Salomonsson et al., 2002; Xanthou et al., 2001).
• ectopic GCs are defined as T and B cell aggregates of proliferating cells with a network of follicular dendritic cells and activated endothelial cells.
• GC-like structures formed within the target tissue also portray functional properties with production of autoantibodies (anti-Ro/SSA and anti-La/SSB) (Salomonsson and Jonsson, 2003).
• autoantibodies anti-Ro/SSA and anti-La/SSB
• RA systemic autoimmune diseases
• chemokines CXCLl 3, CCL21 and lymphotoxin (LT)- ⁇ detected on follicular center and mantle zone B cells.
• Multivariate regression analysis of these analytes identified CXCLl 3 and LT- ⁇ as the solitary cytokines predicting GCs in rheumatoid synovitis (Weyand and Goronzy, 2003). Recently CXCLl 3 and CXCR5 in salivary glands has been shown to play an essential role in the inflammatory process by recruiting B and T cells, therefore contributing to lymphoid neogenesis and ectopic GC formation in SS (Salomonsson et al, 2002).
• Psoriasis is a chronic skin disease of scaling and inflammation that affects 2 to 2.6 percent of the United States population, or between 5.8 and 7.5 million people. Although the disease occurs in all age groups, it primarily affects adults. It appears about equally in males and females. Psoriasis occurs when skin cells quickly rise from their origin below the surface of the skin and pile up on the surface before they have a chance to mature. Usually this movement (also called turnover) takes about a month, but in psoriasis it may occur in only a few days.
• psoriasis results in patches of thick, red (inflamed) skin covered with silvery scales. These patches, which are sometimes referred to as plaques, usually itch or feel sore. They most often occur on the elbows, knees, other parts of the legs, scalp, lower back, face, palms, and soles of the feet, but they can occur on skin anywhere on the body.
• the disease may also affect the fingernails, the toenails, and the soft tissues of the genitals and inside the mouth. While it is not unusual for the skin around affected joints to crack, approximately 1 million people with psoriasis experience joint inflammation that produces symptoms of arthritis. This condition is called psoriatic arthritis.
• Psoriasis is a skin disorder driven by the immune system, especially involving a type of white blood cell called a T cell.
• T cells help protect the body against infection and disease.
• T cells are put into action by mistake and become so active that they trigger other immune responses, which lead to inflammation and to rapid turnover of skin cells.
• psoriasis T cells are put into action by mistake and become so active that they trigger other immune responses, which lead to inflammation and to rapid turnover of skin cells.
• psoriasis there is a family history of psoriasis.
• researchers have studied a large number of families affected by psoriasis and identified genes linked to the disease. People with psoriasis may notice that there are times when their skin worsens, then improves. Conditions that may cause flareups include infections, stress, and changes in climate that dry the skin.
• certain medicines, including lithium and beta blockers, which are prescribed for high blood pressure may trigger an outbreak or worsen the disease.
• Infectious diseases Compounds of the present disclosure may be useful in the treatment of infectious diseases, including viral and bacterial infections. As noted above, such infections may be associated with severe localized or systemic inflammatory responses. For example, influenza may cause severe inflammation of the lung and bacterial infection can cause the systemic hyperinflammatory response, including the excessive production of multiple inflammatory cytokines, that is the hallmark of sepsis.
• compounds of the invention may be useful in directly inhibiting the replication of viral pathogens. Previous studies have demonstrated that related compounds such as CDDO can inhibit the replication of HIV in macrophages (Vazquez et al, 2005).
• the compounds of the present disclosure may be administered by a variety of methods, e.g., orally or by injection (e.g. subcutaneous, intravenous, intraperitoneal, etc.).
• the active compounds may be coated in a material to protect the compound from the action of acids and other natural conditions which may inactivate the compound. They may also be administered by continuous perfusion/infusion of a disease or wound site.
• To administer the therapeutic compound by other than parenteral administration it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation.
• the therapeutic compound may be administered to a patient in an appropriate carrier, for example, liposomes, or a diluent.
• Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Liposomes include water-in- oil-in-water CGF emulsions as well as conventional liposomes (Strejan et al., 1984).
• the therapeutic compound may also be administered parenterally, intraperitoneally, intraspinally, or intracerebrally.
• Dispersions can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
• Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases, the composition must be sterile and must be fluid to the extent that easy syringability exists.
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (such as, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
• the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
• Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
• isotonic agents for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, in the composition.
• Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.
• Sterile injectable solutions can be prepared by incorporating the therapeutic compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
• dispersions are prepared by incorporating the therapeutic compound into a sterile carrier which contains a basic dispersion medium and the required other ingredients from those enumerated above.
• the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (i.e., the therapeutic compound) plus any additional desired ingredient from a previously sterile-filtered solution thereof.
• the therapeutic compound can be orally administered, for example, with an inert diluent or an assimilable edible carrier.
• the therapeutic compound and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet.
• the therapeutic compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
• the percentage of the therapeutic compound in the compositions and preparations may, of course, be varied. The amount of the therapeutic compound in such therapeutically useful compositions is such that a suitable dosage will be obtained.
• Dosage unit form refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
• the specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such a therapeutic compound for the treatment of a selected condition in a patient.
• the therapeutic compound may also be administered topically to the skin, eye, or mucosa. Alternatively, if local delivery to the lungs is desired the therapeutic compound may be administered by inhalation in a dry-powder or aerosol formulation. Active compounds are administered at a therapeutically effective dosage sufficient to treat a condition associated with a condition in a patient.
• a "therapeutically effective amount" preferably reduces the amount of symptoms of the condition in the infected patient by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects.
• the efficacy of a compound can be evaluated in an animal model system that may be predictive of efficacy in treating the disease in humans, such as the model systems shown in the examples and drawings.
• the actual dosage amount of a compound of the present disclosure or composition comprising a compound of the present disclosure administered to a subject may be determined by physical and physiological factors such as age, sex, body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the subject and on the route of administration. These factors may be determined by a skilled artisan. The practitioner responsible for administration will typically determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject. The dosage may be adjusted by the individual physician in the event of any complication.
• An effective amount typically will vary from about 0.001 mg/kg to about 1,000 mg/kg, from about 0.01 mg/kg to about 750 mg/kg, from about 100 mg/kg to about 500 mg/kg, from about 1.0 mg/kg to about 250 mg/kg, from about 10.0 mg/kg to about 150 mg/kg in one or more dose administrations daily, for one or several days (depending, of course, of the mode of administration and the factors discussed above).
• Other suitable dose ranges include 1 mg to 10,000 mg per day, 100 mg to 10,000 mg per day, 500 mg to 10,000 mg per day, and 500 mg to 1,000 mg per day. In some particular embodiments, the amount is less than 10,000 mg per day with a range, for example, of 750 mg to 9,000 mg per day.
• a dose may also comprise from about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 micro- gram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1,000 mg/kg/body weight or more per administration, and any range derivable therein.
• a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, etc. can be administered, based on the numbers described above.
• a pharmaceutical composition of the present disclosure may comprise, for example, at least about 0.1% of a compound of the present disclosure.
• the compound of the present disclosure may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein.
• Desired time intervals for delivery of multiple doses can be determined by one of ordinary skill in the art employing no more than routine experimentation. As an example, subjects may be administered two doses daily at approximately 12 hour intervals. In some embodiments, the agent is administered once a day.
• the agent(s) may be administered on a routine schedule.
• a routine schedule refers to a predetermined designated period of time.
• the routine schedule may encompass periods of time which are identical or which differ in length, as long as the schedule is predetermined.
• the routine schedule may involve administration twice a day, every day, every two days, every three days, every four days, every five days, every six days, a weekly basis, a monthly basis or any set number of days or weeks therebetween.
• the predetermined routine schedule may involve administration on a twice daily basis for the first week, followed by a daily basis for several months, etc.
• the invention provides that the agent(s) may taken orally and that the timing of which is or is not dependent upon food intake. Thus, for example, the agent can be taken every morning and/or every evening, regardless of when the subject has eaten or will eat.
• the compounds of the present disclosure may also find use in combination therapies.
• Effective combination therapy may be achieved with a single composition or pharmacological formulation that includes both agents, or with two distinct compositions or formulations, at the same time, wherein one composition includes the oleanolic acid derivative according to the methods of this invention, and the other includes the second agent(s).
• the therapy may precede or follow the other agent treatment by intervals ranging from minutes to months.
• Beta interferons may be suitable secondary agents. These are medications derived from human cytokines which help regulate the immune system. They include interferon ⁇ -lb and interferon ⁇ -la. Betaseron has been approved by the FDA for relapsing forms of secondary progressive MS. Furthermore, the FDA has approved the use of several ⁇ -interferons as treatments for people who have experienced a single attack that suggests multiple sclerosis, and who may be at risk of future attacks and developing definite MS. For example, risk of MS may be suggested when an MRI scan of the brain shows lesions that predict a high risk of conversion to definite MS.
• Glatiramer acetate is a further example of a secondary agent that may be used in a combination treatment.
• Glatiramer is presently used to treat relapsing remitting MS. It is made of four amino acids that are found in myelin. This drug is reported to stimulate T cells in the body's immune system to change from harmful, pro-inflammatory agents to beneficial, anti-inflammatory agents that work to reduce inflammation at lesion sites.
• Another potential secondary agent is mitoxantrone, a chemotherapy drug used for many cancers. This drug is also FDA-approved for treatment of aggressive forms of relapsing remitting MS, as well as certain forms of progressive MS. It is given intravenously, typically every three months. This medication is effective, but is limited by cardiac toxicity. Novantrone has been approved by the FDA for secondary progressive, progressive-relapsing, and worsening relapsing-remitting MS.
• natalizumab Another potential secondary agent is natalizumab.
• natalizumab works by blocking the attachment of immune cells to brain blood vessels, which is a necessary step for immune cells to cross into the brain, thus reducing the immune cells' inflammatory action on brain neurons.
• Natalizumab has been shown to significantly reduce the frequency of attacks in people with relapsing MS.
• patients may be given intravenous corticosteroids, such as methylprednisolone, as a secondary agent, to end the attack sooner and leave fewer lasting deficits.
• corticosteroids such as methylprednisolone
• Other common drugs for MS that may be used in combination with the oleanolic acid derivatives include immunosuppressive drugs such as azathioprine, cladribine and cyclophosphamide.
• COX inhibitors may be used, including arylcarboxylic acids (salicylic acid, acetylsalicylic acid, diflunisal, choline magnesium trisalicylate, salicylate, benorylate, flufenamic acid, mefenamic acid, meclofenamic acid and triflumic acid), arylalkanoic acids (diclofenac, fenclofenac, alclofenac, fentiazac, ibuprofen, flurbiprofen, ketoprofen, naproxen, fenoprofen, fenbufen, suprofen, indoprofen, tiaprofenic acid, benoxaprofen, pirprofen, tolmetin, zomepirac, clopinac, indomethacin and sulindac) and
• Histamine H2 receptor blocking agents may also be used in conjunction with the compounds of the current invention, including cimetidine, ranitidine, famotidine and nizatidine.
• Treatment with acetylcholinesterase inhibitors such as tacrine, donepizil, metrifonate and rivastigmine for the treatment of Alzheimer's and other disease in conjunction with the compounds of the present disclosure is contemplated.
• Other acetylcholinesterase inhibitors may be developed which may be used once approved include rivastigmine and metrifonate.
• Acetylcholinesterase inhibitors increase the amount of neurotransmitter acetylcholine at the nerve terminal by decreasing its breakdown by the enzyme cholinesterase.
• MAO-B inhibitors such as selegilene may be used in conjunction with the compounds of the current invention. Selegilene is used for Parkinson's disease and irreversibly inhibits monoamine oxidase type B (MAO-B). Monoamine oxidase is an enzyme that inactivates the monoamine neurotransmitters norepinephrine, serotonin and dopamine.
• nitric oxide such as acetyl - L-carnitine, octacosanol, evening primrose oil, vitamin B6, tyrosine, phenylalanine, vitamin C, L-dopa, or a combination of several antioxidants may be used in conjunction with the compounds of the current invention.
• NO nitric oxide
• prostaglandins such as acetyl - L-carnitine, octacosanol, evening primrose oil, vitamin B6, tyrosine, phenylalanine, vitamin C, L-dopa, or a combination of several antioxidants may be used in conjunction with the compounds of the current invention.
• compounds of the invention may be combined with one or more of the following: radiation, chemotherapy agents (e.g., cytotoxic agents such as anthracyclines, vincristine, vinblastin, microtubule-targeting agents such as paclitaxel and docetaxel, 5-FU and related agents, cisplatin and other platinum-containing compounds, irinotecan and topotecan, gemcitabine, temozolomide, etc.), targeted therapies (e.g., imatinib, bortezomib, bevacizumab, rituximab), or vaccine therapies designed to promote an enhanced immune response targeting cancer cells.
• chemotherapy agents e.g., cytotoxic agents such as anthracyclines, vincristine, vinblastin, microtubule-targeting agents such as paclitaxel and docetaxel, 5-FU and related agents, cisplatin and other platinum-containing compounds, irinotecan and topotecan, gemcitabine, temozolomi
• compounds of the invention may be combined with one or more of the following: corticosteroids, methotrexate, anti-TNF antibodies, other TNF-targeting protein therapies, and NSAIDs.
• corticosteroids for the treatment of prevention of cardiovascular diseases, compounds of the invention may be combined with antithrombotic therapies, anticholesterol therapies such as statins (e.g., atorvastatin), and surgical interventions such as stenting or coronary artery bypass grafting.
• antiresorptive agents such as bisphosphonates or anabolic therapies such as teriparatide or parathyroid hormone.
• compounds of the invention may be combined with antidepressants (e.g., imipramine or SSRIs such as fluoxetine), antipsychotic agents (e.g., olanzapine, sertindole, risperidone), mood stabilizers (e.g., lithium, valproate semisodium), or other standard agents such as anxiolytic agents.
• antidepressants e.g., imipramine or SSRIs such as fluoxetine
• antipsychotic agents e.g., olanzapine, sertindole, risperidone
• mood stabilizers e.g., lithium, valproate semisodium
• other standard agents such as anxiolytic agents.
• compounds of the invention may be combined with anticonvulsant agents (e.g., valproate semisodium, gabapentin, phenytoin, carbamazepine, and topiramate), antithrombotic agents (e.g., tissue plasminogen activator), or analgesics (e.g., opioids, sodium channel blockers, and other antinociceptive agents).
• anticonvulsant agents e.g., valproate semisodium, gabapentin, phenytoin, carbamazepine, and topiramate
• antithrombotic agents e.g., tissue plasminogen activator
• analgesics e.g., opioids, sodium channel blockers, and other antinociceptive agents.
• BH4 tetrahydrobiopterin
• BH4 is a co factor for constitutive forms of nitric oxide synthase, and may be depleted by reactions with peroxynitrite. Peroxynitrite is formed by the reaction of nitric oxide and superoxide.
• superoxide can deplete normal, beneficial levels of nitric oxide by converting NO to peroxynitrite.
• the resulting depletion of BH4 by reaction with peroxynitrite results in the "uncoupling" of nitric oxide synthases so that they form superoxide rather than NO.
• RAW264.7 macrophages were pre- treated with DMSO or drugs for 2 hours, then treated with recombinant mouse IFN ⁇ (Sigma) for 24 hours. NO concentration in media was determined using the Griess reagent system (Promega). Cell viability was determined using WST-I reagent (Roche). STAT3 phosphorylation. HeLa cells were treated with the indicated compounds and concentrations for 6 hours and subsequently stimulated with 20 ng/ml recombinant human IL- 6 (R&D Systems) for 15 minutes. Lysates were immunob lotted with antibodies against phosphorylated or total STAT3 (Cell Signaling). iNOS induction qPCR.
• RAW264.7 mouse macrophage cells were pre-treated for 2 hours with compounds at the indicated concentrations and subsequently stimulated with 10 ng/ml IFN ⁇ for an additional 2 hours.
• mRNA levels of iNOS were quantified by qPCR and are shown relative to the vehicle-treated IFN ⁇ -stimulated sample which was normalized to a value of 1. Values are averages of duplicate PCR reactions, each with triplicate wells.
• RAW264.7 cells were pre-treated for 2 hours with indicated compounds and subsequently stimulated with 10 ng/ml IFN ⁇ for an additional 24 hours. iNOS and COX-2 protein levels were assayed by immunob lotting.
• Actin was used as a loading control.
• Nrf2 target gene induction MDA-MB-435 human melanoma cells were treated with vehicle (DMSO) or the indicated compounds and concentrations for 16 hours.
• DMSO vehicle
• HO-I thioredoxin reductase- 1
• ⁇ -GCS ⁇ -glutamylcysteine synthetase
• ferritin heavy chain mRNA levels were quantified using qPCR and were normalized relative to a DMSO- treated sample run in parallel. Values are averages of duplicate wells. Primer sequences are as follows.
• HO-I FW TCCGATGGGTCCTTACACTC (SEQ ID NO:1)
• HO-I REV TAGGCTCCTTCCTCCTTTCC
• TrxRl FW GCAGCACTGAGTGGTCAAAA (SEQ ID NO:3)
• TrxRl REV GGTCAACTGCCTCAATTGCT (SEQ ID NO:4), ⁇ -GCS FW: GCTGTGGCTACTGCGGTATT (SEQ ID NO:5), ⁇ -GCS REV ATCTGCCTCAATGACACCAT (SEQ ID NO:6), Ferritin HC FW: ATGAGCAGGTGAAAGCCATC (SEQ ID NO:7), Ferritin HC REV: TAAAGGAAACCCCAACATGC (SEQ ID NO:8,
• Step 2 Compound Solubility Testing Procedures using the MilliporeTM Multiscreen® Solubility Filter Plate.
• Amine 402-14 was synthesized from acid 1 (Honda et ah, 2000b) in 3 steps (Scheme 1). Acid 1 (Honda et ah, 2000b) was treated with DPPAZEt 3 N to give the corresponding azide 402-11 in 90% yield. The Curtius rearrangement of compound 2 gave isocyanate 3, which was treated with concentrated HCl to give amine 402-14 in quantitative yield.
• Scheme 2 :
• Cyclopropanecarbonyl chloride was prepared by the reaction of cyclopropanecarboxylic acid with oxalyl chloride (1 eq.) in the presence of catalytic amount of DMF. After stirring at 0 °C for 2 h, the reaction mixture was used to react with amine 402-52 directly.
• Compound 12 Compound 11 (41 mg, 0.082 mmol), NH 2 OH-HCl (9.1 mg, 0.13 mmol), EtOH (2 mL), and water (0.2 mL) were mixed together and heated at 60 °C for 4 h. EtOH was removed by evaporation, and the white slurry obtained was extracted with EtOAc. The combined extracts were washed with water, dried with MgSO 4 , and concentrated.
• Cyclopropyl acid chloride was prepared according to the following procedure: to a solution of cyclopropylcarboxylic acid (258 mg, 3.00 mmol) and DMF (1 drop, cat.) in CH 2 Cl 2 (3 mL) at 0 °C was added oxalyl chloride (0.254 mL 3.0 mmol). The mixture was stirred at 0 °C 2 hrs to give a solution of cyclopropyl acid chloride.
• Salomonsson et al Scand. J. Immunol, 55(4):336-342, 2002. Salvarani et al, Curr. Opin. Rheumatol. 1998; 10:299-305, 1998.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurology (AREA)
• Immunology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Cardiology (AREA)
• Diabetes (AREA)
• Heart & Thoracic Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Dermatology (AREA)
• Hematology (AREA)
• Rheumatology (AREA)
• Obesity (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Hospice & Palliative Care (AREA)
• Urology & Nephrology (AREA)
• Psychology (AREA)
• Oncology (AREA)
• Pain & Pain Management (AREA)
• Pulmonology (AREA)
• Endocrinology (AREA)
• Toxicology (AREA)
• Emergency Medicine (AREA)
• Psychiatry (AREA)
• Communicable Diseases (AREA)
• Ophthalmology & Optometry (AREA)

Priority Applications (21)

Applications Claiming Priority (4)

Publications (1)

Family

ID=40833485

Family Applications (1)

Country Status (25)

Cited By (39)

Families Citing this family (23)

Family Cites Families (115)

• 2009
  • 2009-04-20 JP JP2011505259A patent/JP5529851B2/ja active Active
  • 2009-04-20 PT PT09732992T patent/PT2276493T/pt unknown
  • 2009-04-20 AU AU2009237579A patent/AU2009237579C1/en active Active
  • 2009-04-20 SI SI200931910T patent/SI2276493T1/sl unknown
  • 2009-04-20 WO PCT/US2009/041172 patent/WO2009129546A1/en not_active Ceased
  • 2009-04-20 CA CA2721838A patent/CA2721838C/en active Active
  • 2009-04-20 CN CN201410341447.5A patent/CN104177468B/zh active Active
  • 2009-04-20 EA EA201001555A patent/EA019263B1/ru unknown
  • 2009-04-20 RS RS20181534A patent/RS58392B1/sr unknown
  • 2009-04-20 NZ NZ588710A patent/NZ588710A/xx unknown
  • 2009-04-20 KR KR1020107025722A patent/KR101735807B1/ko active Active
  • 2009-04-20 ES ES09732992T patent/ES2703274T3/es active Active
  • 2009-04-20 HU HUE09732992A patent/HUE041221T2/hu unknown
  • 2009-04-20 MX MX2010011438A patent/MX2010011438A/es active IP Right Grant
  • 2009-04-20 TW TW098113103A patent/TWI453023B/zh active
  • 2009-04-20 PL PL09732992T patent/PL2276493T3/pl unknown
  • 2009-04-20 DK DK09732992.4T patent/DK2276493T3/da active
  • 2009-04-20 CN CN200980123340.0A patent/CN102083442B/zh active Active
  • 2009-04-20 EP EP09732992.4A patent/EP2276493B1/en active Active
  • 2009-04-20 HR HRP20182060TT patent/HRP20182060T1/hr unknown
  • 2009-04-20 US US12/426,778 patent/US8124799B2/en active Active
  • 2009-04-20 LT LTEP09732992.4T patent/LT2276493T/lt unknown
• 2010
  • 2010-10-17 IL IL208758A patent/IL208758A/en active IP Right Grant
  • 2010-10-25 ZA ZA2010/07586A patent/ZA201007586B/en unknown
  • 2010-11-17 CO CO10143959A patent/CO6311071A2/es active IP Right Grant
• 2012
  • 2012-01-23 US US13/356,455 patent/US8440854B2/en active Active
• 2013
  • 2013-04-11 US US13/861,208 patent/US9102681B2/en active Active
• 2015
  • 2015-06-29 US US14/753,297 patent/US9670147B2/en active Active
• 2017
  • 2017-06-06 US US15/615,393 patent/US10093614B2/en active Active
• 2018
  • 2018-08-28 US US16/115,028 patent/US10556858B2/en active Active
• 2019
  • 2019-02-13 CY CY20191100194T patent/CY1121586T1/el unknown
• 2020
  • 2020-02-10 US US16/786,429 patent/US11091430B2/en active Active
• 2021
  • 2021-07-09 US US17/305,537 patent/US11919838B2/en active Active
• 2024
  • 2024-02-06 US US18/433,950 patent/US12358866B2/en active Active
• 2025
  • 2025-05-30 US US19/223,832 patent/US20250353813A1/en active Pending

Non-Patent Citations (2)